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7SUMMARY
From October 1985 to March 1986 208 children 
(128 males, 80 females) were admitted to the Royal 
Hospital for Sick Children, Glasgow with suspected 
respiratory infection. This hospital is the largest 
paediatric centre in the West of Scotland with annual 
admissions for respiratory infections of 1903 children 
(79.5%) . When comparing the total number of children 
under study and total number of admissions during the 
study period, the majority of admissions (45%) were 
children under one year of age with the highest 
incidence of respiratory infections in November (30.7%) 
at the RHSC. In this study RSV infection was much 
greater in infants from Inner Glasgow predominantly 
Drumchapel, Castlemilk, Toryglen, High Possil (65.8%) , 
and Clydebank (12.6%) which have a higher proportion of 
low income families and households with two or more 
indicators of deprivation. The reverse situation was 
found in Bearsden/Milngavie and Eastwood where the 
proportion of RSV infections was 2.7% and 5.4% 
respectively.
A full history and clinical examination was 
carried out in each case, and data recorded on a 
special form suitable for computer analysis. This 
included admission history, diagnosis classified into 
Upper Respiratory Tract Infection (URTI), pneumonia,
bronchiolitis, chronic lung disease and others.
Clinical parameters such as maximum respiratory rate, 
time to establish normal respiratory rate, 
physiotherapy and length of tube feeding were 
evaluated. Nasopharyngeal secretions (NPS) were 
collected on admission or first day of symptoms if 
already admitted, and subsequently repeated on days 3, 
5, and 7 when possible. Plastic disposable collecting 
mucus traps with an attached feeding tube (5fg) were 
used to obtain the secretions. A portion of the 
secretions was cultured in bacteriological media and 
the remainder was transferred to virus transport medium 
(VTM) in a 1/10 dilution. After centrifugation of the 
specimen suspension, the supernatant fluid was used for 
virus isolation, embryonated hen egg inoculations and 
assay for alpha-interferon (IFN-(>{ ) . The cell pellet
was examined by direct immunofluorescence using a 
respiratory syncytial virus (RSV) specific monoclonal 
antibody.
IFN-/)^ levels were determined by a
commercially available immunoradiometric assay. The
1 ? stest utilises an I labelled highly specific
monoclonal antibody (Yok 5/19) to leucocyte IFN- <X . 
Prior to application of the test in the clinical study 
it was important to determine the assay performance in 
terms of sensitivity and specificity parameters with 
special reference to the clinical specimens to be
9examined. The reproducibility of the test was 
evaluated when the mean values for each point of 
different standard curves were plotted together. A 
standard curve was used to interpolate IFN- c/ values 
for unknown samples of NPS. The variability found 
between the standard curves using different kits of 
reagents were similar for each point and varied from 21 
to 31%. The sensitivity of IRMA for NPS was also 
evaluated and the test was able to detect as little as 
0.2 IU/ml in a diluted clinical specimen.
Experimentation on the specimens was carried out to 
determine heat stability and lability to trypsin.
Using recombinant IFN- oL or a pool of specimens 
containing endogenous IFN- oi , treatment with heat 
caused partial inactivation.
The protein characteristics of IFN- o<{ was 
confirmed when standard preparations of IFN- and 
clinical specimens containing endogenous IFN- ^  were 
treated with trypsin for trypsin sensitivity. In 
these experiments trypsin treatment completely 
inactivated both recombinant and endogenous IFN- (X .
In this study neutralization-blocking 
experiments were performed in order to demonstrate the 
specificity of the Yok 5/19 monoclonal antibody in 
detecting IFN- o<_ . In both cases using standards and 
specimens, it was possible to neutralize almost 100% of the 
activity with very little residual IFN- o( after
blocking, demonstrating an absolute specificity in this 
test.
It was clear for these studies that this 
technique is well devised, reproducible, rapid and 
sensitive.
A clinical study was carried out to determine 
RSV and IFN-o£ status in children with respiratory 
infections.
The distribution of age in RSV positive and 
negative cases showed a higher proportion of RSV 
positive cases from 1 to 6 months of age whereas a 
higher proportion of RSV negative cases were from six 
to eight months.
IFN- q( positivity was found in a higher 
proportion of younger children and in those with a 
longer hospital stay.
A male predominance was found in this study 
and boys were admitted to hospital in higher numbers, 
whether RSV positive or negative.
The presence of IFN- cxf in NPS was 
statistically significant in cases of pneumonia, 
whether RSV positive or not, and was found in the 
majority of NPS from patients with a maximum 
respiratory rate greater than 60/min. The viral 
aetiology of RSV negative/IFN- o( positive pneumonia was 
unknown in the majority of cases.
In this study it was possible to demonstrate
IFN-0^ in the NPS of a relatively high percentage of 
children (38%) with RSV infection compared to other 
studies. In RSV positive bronchiolitic patients, IFN- 
was present in 65% compared to only 31% in 
bronchiolitic patients due to other causes.
Adenovirus infection in patients studied here was 
associated with an IFN-£x{ mean level of 167.8 IU/ml. 
When the RSV positive data on specimens and cases were 
analysed, it appeared that when IFN-<p{ is induced, its 
presence is consistently associated with the 
persistence of the virus in secretions. IFN-o( is 
likely to be present at the first testing on admission 
in NPS of children who will produce IFN- o( during the 
course of RSV infection.
Of the total population studied, 58.6% were 
found to be RSV positive/IFN- o( positive compared to 
41.4% RSV positive/IFN- o( negative cases. The study 
results demonstrated that RSV positive patients were 
statistically different from those RSV negative 
patients for most of the clinical parameters analysed.
Although trends in various clinical 
parameters were seen linking RSV disease severity with 
IFN- positivity, the only clinical finding which was 
shown to be statistically significant with the 
demonstration of IFN- in NPS was the duration of tube 
feeding.
The diagnosis of RSV was demonstrated in 89
12
cases by the direct immunofluorescence technique when 
culture results were negative. The remaining 22 cases 
were positive by culture and by fluorescence. It was 
observed that RSV positive NPS confirmed only by 
fluorescence were more likely to be in the low positive 
IFN- M  range of 2-20 IU/ml than culture positive 
samples which had higher mean IFN-oC level.
To obtain a better isolation rate for 
influenza virus, clinical specimens were also 
inoculated into embryonated hen eggs but these efforts 
were unrewarding in the present study.
Streptococcus_pneumoniae was the bacterium 
most frequently isolated in NPS in all the clinical 
parameters analysed.
This study does not give a clear indication 
where IFN- o( fits into the pathogenesis of RSV 
infection in association with bronchiolitis but has 
contributed to the knowledge of this infection.
However, the presence of IFN- was associated with 
more persistent RSV infection and could be considered 
to provide additional information on the likely outcome 
of this disease or prompt the use of specific antiviral 
chemotherapy.
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CHAPTER I 
INTRODUCTION
Part I
Acute respiratory infections are the 
commonest illnesses in childhood comprising 
approximately 50% of all illnesses in children under 
five years (Phelan et a 1 . , 1982(a)). Among these
infections, acute bronchiolitis is regarded as the most 
important respiratory illness in infants under six 
months of age, with a peak incidence at two to four 
months (Simpson et al. , 1978) .
It is now well established that respiratory 
syncytial virus (RSV) is the major cause of more 
serious respiratory infection in infancy. it is 
responsible for approximately 80% of cases of 
bronchiolitis, 12% of cases of
laryngotracheobronchitis, 20% of cases of pneumonia and
15% of cases of bronchitis, in the first year of life 
(Phelan et al., 1982(a)). Although it appears to play 
a major role in the aetiology of bronchiolitis, the 
clinical features have also been described during 
infections with adenovirus types 3, 7 and 21,
parainfluenza virus type 3, rhinovirus, herpes simplex 
type 1, certain serotypes of enterovirus and Mycoplasma 
pneumoniae (Simpson et al., 1978; Tercier, 1983).
1.1 EPIDEMIOLOGY OF RSV INFECTIONS
RSV presents a predictable pattern of illness
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in the community. Epidemics have been reported from 
many countries, including Australia (Lewis et al., 
1961), U.K. (Peacock et al., 1961; Mufson et al.,
1973) where the peak of the epidemic corresponds with 
the coldest month of the year. In the United States 
there seems more seasonable variation in that the peak 
varies from late autumn, winter or early spring and 
usually lasts for 4-5 months (Martin et al., 1978; De
Silva et al., 1981).
Host Factors
There are some predisposing risk factors 
which can cause a more severe disease. The pattern of 
illness varies considerably with age and with the 
genetic constitution of the infected person (Phelan et 
al . , 1982 (a) ) .
Sex
Although the sex of the patient does not 
affect the frequency of isolation of RSV, significantly 
more males than females are admitted to hospital with 
RSV infection in the ratio 1.3 or 1.4 to 1.0 (Stott et 
al., 1985).
Gestational age
During the first year of life infants born 
weighing less than 1500 g have a hospitalization rate 
due to RSV five times greater than infants born 
weighing more than 2500 g (Phelan 
et al., 1982 (a) ) .
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Congenital malformations
The risk of infection in babies with 
congenital malformations, especially cardiac disease 
who are admitted to hospital with RSV infection or who 
acquire it during hospitalization, have an increased 
risk of severe or fatal disease, mainly due to 
pulmonary hypertension. Infants with pulmonary 
hypertension are less able to compensate for the 
altered distribution of ventilation that occurs with 
RSV infection (McDonald et al . , 1982) .
Breast feeding
Observations of RSV infection related to 
breast-feeding halves the risk of admission to hospital 
in infants with RSV infection (Pullan et al. , 1980) .
Many other social factors such as maternal care, a 
mother's smoking, and the presence of another child in 
the same room at night tend to be combined factors 
increasing the risk of infection (Phelan et al.,
1982 (a) ) .
Environmental factors
In a low income setting, the quality of
maternal care seems to be the most important
environmental factor in determining the likelihood of 
admission of an infant to hospital with RSV infection 
(Phelan et al., 1982(a)). Here, the family size is 
often larger, living quarters more crowded and children
are more likely to be exposed to a relatively larger
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infectious dose (Glezen et a l ., 1977; Glezen et al.,
1981) .
1.1.2 CLINICAL PICTURE OF RSV-BRONCHIOLITIS
The clinical picture of RSV-bronchiolitis is 
well known. The incubation period from exposure to 
first symptoms is about 4 days. The virus is excreted 
for variable periods, probably depending on severity of 
illness and immunological status (McIntosh, 1983) .
Most infants with lower respiratory tract 
illness shed virus for 5 to 12 days after hospital 
admission and the first signs of infection of the 
infant with RSV are coryzal onset of one to several 
days followed by tachypnoea and signs of respiratory 
distress, sometimes accompanied by poor feeding 
(Simpson et al., 1978; McIntosh et al., 1980).
The chest becomes overinflated and a dry 
repetitive cough, restlessness and cyanosis may be 
present (Simpson et al., 1978). This hyperinflation
of the lungs displaces the liver and spleen downward, 
so that they become easily palpable. These signs in 
an infant with bronchiolitis do not necessarily 
indicate heart failure (Reynolds, 1972). A cough 
appears more often after an interval of 1 to 3 days and 
the child begins to wheeze audibly. Auscultation 
often reveals diffuse rhonchi, fine-rales and wheezes 
(McIntosh, 1983).
The temperature is seldom above 38°C. Some
infants with RSV bronchiolitis show signs of 
dehydration due to inadequate fluid intake and increase 
water loss from the respiratory tract (Simpson et al., 
1978) .
The white cell count is usually normal but 
when elevated the differential count may be normal or 
shifted either to the right or left (Reynolds et al., 
1972) .
Arterial blood gas estimations often show a
low pC>2 and a normal or elevated pCC^ . The degree of
elevation corresponds with the severity of the illness 
(Wohl et al., 1978).
The chest-X-ray findings are frequently 
normal. If the illness progresses, cough and wheezing
increase, air hunger and evidence of hyperexpansion of
the chest (particular intercostal and subcostal 
retraction) are evident (McIntosh, 1983) .
The lung fields appear abnormally translucent 
and there are sometimes small areas of collapse 
(Reynolds et al., 1972). Peribronchial thickening or
interstitial pneumonia is seen in 50 to 80 per cent of 
the cases and segmental consolidation occurs in 10 to 
25% (McIntosh, 1983).
1.1.3 PATHOLOGICAL FEATURES
The earliest lesions occur in small airways 
ranging from 75-300 urn in diameter. Histologically,
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the most important lesion is obstruction of the 
bronchioles caused by thickening of the bronchiolar 
walls with oedema, lymphocytic cellular infiltrate and 
also by obstruction of the lumen with plugs of mucus 
and cellular debris (Simpson et al., 1978; Reynolds,
1972). In severe cases desquamation of the epithelial 
lining may occur. These changes are distributed 
throughout the lungs and the bronchi are much less 
severely affected than the bronchioles (Simpson et
al., 1978).
1.1.4 DIAGNOSIS
The method for detecting RSV is by collecting 
respiratory secretions from the nasopharynx by 
aspiration using a mucus trap (Fenner et al., 1976) . 
Because of the extreme lability of RSV, specimens are 
transferred straight into the culture tube at the 
bedside or transported at 4°C to the laboratory for 
isolation and propagation (Treuhaft et al. , 1985) .
Isolation from stored specimens is rarely successful 
but under favourable conditions HEp-2 (continuous human 
epithelioma cells) or (Bristol) HeLa cells (cervical 
carcinoma) are the most useful tissue culture cells for 
syncytial cytopathology (Pringle, 1985).
Human RSV can grow in a wide range of non­
human cells and the relative susceptibility of 
different cells depends to some extent on the passage 
history of the virus strain employed (Pringle, 1985).
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Thus, success in culturing the virus depends on 
frequent monitoring of cell lines for sensitivity 
(McIntosh, 1983).
Eagle's minimum essential medium (MEM), 
preferably supplemented with non-essential amino acids 
and glutamine is a satisfactory maintenance medium for 
RSV-infected cells (Pringle, 1985; Marquez et al., 
1967) .
Direct examination of RSV antigen can be 
detected in respiratory tract cells and in cells from 
virus isolation tubes by using the fluorescent antibody 
technique. It is an essential requisite for an 
unequivocal diagnosis by direct fluorescence that 
preparations contain a large number of intact 
nasopharyngeal cells (McQuillin et al. , 1968) .
Monoclonal antibodies against RSV are preferable to 
animal anti RSV sera for use in antigen detection 
tests, since they have excellent sensitivity and 
specificity (Bell et al., 1983).
The use of monoclonal antibodies gives clear 
staining of cytoplasmic inclusions with very little 
non-specific fluorescence (Pothier et al., 1985).
The capability to provide a rapid diagnosis 
of RSV infection is an important clinical commitment, 
because of the need to control the potential spread of 
this infection in a hospital setting (Cheeseman et al.,
1986) .
3^
Examination of acute and convalescent sera 
for a rise in complement fixation (CF) or neutralizing 
antibody to RSV is often disappointing in the infant. 
Nevertheless, if such a rise is found, the diagnosis is 
clear (McIntosh, 1983). In the convalescent period, a 
serological diagnosis by finding a high titre by CF or 
the presence of specific IgM, may be the only way of 
making a retrospective diagnosis.
1.1.5 TREATMENT
The management of the baby with RSV 
bronchiolitis depends on humidified oxygen therapy and 
good nursing care (Phelan et al. , 1982 (b) ) .
Severely affected babies are best nursed in a 
plastic oxygen cot which allows high concentrations of 
oxygen (Wohl et al., 1978) . The hypoxaemia present in 
most infants is usually caused by ventilation-perfusion 
abnormalities and it is generally corrected with 
inspired O2 of 30 to 40% (Wohl et al. , 1978) .
Intravenous or oral rehydration
Mild dehydration is common and in some 
infants fluids may have to be given for a day or two 
either by a gastric tube or by the intravenous route 
(Reynolds, 1972).
Antibiotic cover
As a virus disease antibiotics have no ■ effect^ 
on the progress of the illness. At the first sign of 
secondary bacterial infection, a broad-spectrum
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antibiotic has been known to be beneficial (Reynolds, 
1972) .
Bronchodilator drugs such as epinephrine, 
isoproterenol and aminophyl1ine are commonly used in 
bronchiolitis, but they do not have a profound effect 
on the course of the disease (Reynolds, 1972) .
Specific antivirals
Ribavirin is an antiviral drug that has 
recently been approved by the Food Drug Administration 
(USA) and the Committee on Safety of Medicines (UK) in 
an aerolized form for the therapy of RSV infection in 
those patients who do not require assisted ventilation. 
It is a synthetic nucleoside analog (1-^-D- 
ribofuranosyl-1,2,4,-triazole-3-carboxamide) resembling 
guanosine and ionosine; it appears to interfere with 
the expression of messenger RNA and inhibit viral 
protein synthesis.
Trials of ribavirin treatment of infants 
hospitalized with respiratory syncytial virus disease 
were begun in 1981 and have involved both normal 
infants and those with underlying diseases (Isaacs,
1987). It has been administered orally, intravenously 
and by aerosol to adults but only in aerosol form to 
children. Particles small enough to reach the lower 
respiratory tract (5 um) are delivered via an oxygen 
hood or tent for an average of three to five days for
18 hours each day.
Ribavirin aerosol was administered for only 
12 hours in one study and the infants improved more 
rapidly than those given placebo, but the difference 
between the treated and placebo groups were less 
obvious than in another two trials that had a large 
dose (Taber et al., 1983). In these studies the 
treatment was administered for 18-20 hours each day and 
the difference in rate of recovery was most obvious for 
lower respiratory tract signs such as cough, 
tachypnoea, chest recession and crepitations in the 
lung fields (Barry et al., 1986; Hall et al., 1983).
Ribavirin may well have a place in the 
treatment of RSV bronchiolitis in infants who are 
likely to be severely affected, such as those with 
immunodeficiency, congenital heart disease, and 
bronchopulmonary dysplasia (Barry et al. , 1986) . At
the present time, it has not been possible to 
anticipate the severity of the bronchiolitis during the 
course of the disease by observed parameters at the 
time of admission to hospital. This provides 
difficulty in deciding which cases should be treated 
with this costly preparation.
1.1.6 PROGNOSIS
The mortality of hospitalized infants with 
RSV infection of the lower respiratory tract is about 2
per cent (Simpson et al. , 1978) . The progress is
clearly worst in infants with underlying disease of the 
neuromuscular, pulmonary, cardiovascular, or 
immunologic systems (Gardner et al . , 1967; Downham et
al., 1975; McIntosh, 1983).
A number of investigators have linked RSV 
infection with the sudden infant death syndrome (SIDS), 
because it has been described that a good proportion of 
infants with RSV lower respiratory tract infection die 
suddenly and unexpectedly. To date no studies have 
demonstrated evidence of a systemic viral infection 
indicated by viremia or elevated interferon (IFN)
(Kelly et al. , 1982) . This is consistent with the
findings in most studies involving viral isolation in 
SIDS where recovery of viruses has been limited to the 
respiratory and gastrointestinal tracts (Seto et al., 
1978). One study has reported an association between 
infection with RSV and prolonged apnoeic episodes. In 
a small proportion of affected infants this progresses 
to the point where cardiac arrythmias followed by death 
occur with a fatal outcome (Bruhn et al. , 1977).
Children who suffer acute bronchiolitis in 
infancy have a high incidence of respiratory problems 
in succeeding years, whether or not their initial 
illness was severe enough to require admission to 
hospital (Webb et al., 1985). More than 50% of 
children continue to wheeze recurrently. Atopy does
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not seem to be an additional factor or play an 
important role since the low level of skin sensitivity 
has shown no difference between children with and 
without continuing symptoms (Sims' et al., 1981; Webb
et al. , 1985) .
1.1.7 PREVENTION
The efforts to develop an effective vaccine 
have been unsuccessful (Wohl et al.# 1978).
Approximately 20 years ago a formalin-inactivated RSV 
vaccine was evaluated in infants and young children. 
This vaccine stimulated moderately high levels of serum 
antibodies, as measured by the CF assay, but failed to 
induce resistance to infection caused by RSV (Kapikian 
et al., 1969). Infants receiving formalin-inactivated 
RSV vaccine developed more serious lower respiratory 
tract disease when infected with the wild virus at a 
latter natural challenge (Chanock et al., 1970) . The 
treatment of RSV with formalin appears to have altered 
the epitopes of the F and G glycoproteins that 
stimulate neutralizing antibodies, with the result that 
the immune response consisted largely of non-functional 
antibodies. These may have participated in a 
pulmonary Arthus reaction during RSV infection leading 
to the increase in clinical sequelae (Murphy et al., 
1986).
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Vaccines prepared from temperature sensitive 
mutants of RSV have also proved unsatisfactory as the 
mutants used were unstable showing some latter 
reversion to wild type virulence (Chanock et al.,
1977).
1.1.8 MECHANISMS OF THE DISEASE 
Anatomical considerations
As adults complain mainly of upper 
respiratory tract symptoms, replication of the virus 
may be limited primarily to the upper airways (Wohl et 
al., 1978). The lack of severe symptoms referable to
the small airways may therefore be related to an 
anatomic difference between the infant and the adult 
lung (Wohl et al., 1978). The conducting airways 
consist of 18 branching generations from the hilum and 
this series of dichotomous branches is completed by the 
sixteenth week of fetal life. Thus, at birth, the 
number of conducting airways is the same as in the 
adult lung. However, peripheral airways are 
disproportionately narrow in the early years of life 
(Hogg et al., 1968) and the disease in small airways
would have a greater effect on increasing the 
resistance to flow in the young infant than in the 
adult (Wohl et al., 1978).
Immunological considerations
The available data on the possible 
immunological explanation for the severity of the
illness in the young infant are contradictory and 
difficult to interpret. Antibodies against some 
components of RSV may not only fail to protect but may 
be involved in the pathogenesis of severe bronchiolitis 
(Ogilvie et al. , 1981) .
Chanock and co-workers have postulated that 
the incidence of bronchiolitis is highest in the first 
2 months of life, when maternally acquired antibody 
concentrations are greatest leading to a type 3 
antigen-antibody response or Arthus reaction. He 
proposed that the interaction of serum antibody and 
viral antigens in the lungs plays an important role in 
producing the disease manifestations which are 
characteristic of RSV illness of early infancy, 
especially the bronchiolar obstruction of bronchiolitis 
(Chanock et al., 1970).
However, Lamprech and co-workers postulated 
that neutralizing antibody might be protective. They 
suggested that the presence of maternally acquired 
neutralizing antibody prevents spread of the disease 
(Lamprech et al., 1976). In a prospective study which 
studied one hundred newborn infants during a one year 
period, the authors suggest that the mean titre of 
maternal IgG antibody to RSV was significantly higher 
in those mothers whose babies remained uninfected than 
in those whose babies had proven RSV infection before 
six months of age (Ogilvie et al . , 1981).
Other investigators have suggested that 
secretory IgA containing RSV antibody might be 
transmitted to the newborn in colostrum and breast-milk 
(Ogilvie et al . , 1981; Downham et al . , 1976).
A relationship between a low frequency of 
breast-feeding and a high incidence of RSV disease in 
infants was first suggested by Glezen and Denny (1973) 
in a survey of respiratory disease in the United States 
(Glezen et al. , 1973). Further epidemiological 
evidence of the protective effect of breast-feeding 
demonstrated that a significantly lower percentage of 
infants admitted to hospital with RSV infection had 
been breast fed compared with age-matched controls 
(Downham et al., 1976).
The role of secretory IgA in protecting the 
infant has been studied by Scott and Gardner, who found 
IgA immunoglobulin to be consistently present at 
detectable concentrations. Neutralizing activity 
against RSV in secretions was due to specific IgA 
antibody (Scott et al., 1974).
Gardner and McQuillin have postulated that 
there is a prior sensitizing to RSV infection, leading 
to the production of IgE antibody. They suggested 
that the reaction is more akin to type 1 
hypersensitivity. They found scant virus in 
impression smears of the lungs using immunofluorescence
staining in two children who died of bronchiolitis and 
abundant virus in one who died of pneumonia. 
Immunoglobulins (class unspecified) were present in the 
tissue preparation of bronchiolitis but not in those 
from cases of RSV-pneumonia. These observations were 
not consistent with a type 3 reaction which had been 
suggested by Chanock (Gardner et al., 1970(b);
McIntosh et al., 1980).
Studies have demonstrated RSV specific IgE 
bound to exfoliated nasopharyngeal epithelial cells and 
histamine release from patients with all forms of 
illness due to RSV infection (Welliver et al., 1981).
It appears to be more persistently present and in 
higher titre in patients with wheezing due to RSV 
infection than in patients infected with RSV without 
wheeze (Welliver et al., 1983(a)). The degree of RSV 
specific IgE responsiveness was highly correlated with 
the severity of illness as determined by the degree of 
hypoxia. It is postulated that, the production of 
RSV-specific IgE and release of histamine may determine 
the form and severity of illness in most cases of 
lower-respiratory tract illness due to RSV (Welliver et 
al . , 1981) .
The relationship of suppressor cell numbers 
and function to virus-specific IgE response was 
determined in children with RSV infection (Welliver et 
 ^ 1984). Patients with bronchiolitis had fewer
0KT8-po6itive cells during convalescence than patients 
with other forms of illness due to RSV and histamine- 
induced suppression was also reduced in patients with 
bronchiolitis (Welliver et al., 1984).
1.1.9 IMMUNOLOGICAL ASPECTS
It is not fully established if the neonate is 
immunocompetent with regard to his immunological 
functions, since there are numerous quantitative 
differences compared with the adults or older children 
(McIntosh, 1980) . However, studies have shown that 
RSV specific secretory IgA as well as IgG and IgM, 
appear in the respiratory tract as early as the first 
three days after the onset of illness caused by RSV 
infection (Welliver et al., 1983(b). The capacity
of lymphocytes of newborn to mediate antibody dependent 
cellular cytotoxicity against virus-infected target 
cells is thought to be normal (McIntosh, 1980). 
Lymphotoxin production by activated lymphocytes is 
reduced in cord blood but IFN production, on the other 
hand, appears to be normal (McIntosh, 1980; Ray et 
al. , 1967) .
Despite all the scientific work over the past 
20 years to discover the pathogenesis of RSV- 
bronchiolitis, a final verdict on this has not been 
revealed.
Several theories of the pathogenesis of RSV 
disease have been proposed, based on the immunological
immaturity of the infant, a role for serum antibody, a 
delayed hypersensitivity-type reaction, an IgE-mediated 
reaction and non-immunologica1 mechanisms (Stott et 
al ., 1985). Clearly, no firm conclusions are possible
about which immunopathologic mechanisms in 
bronchiolitis should be explored, but interferon 
studies have been few. As techniques have advanced in 
interferon detection the time is opportune to 
investigate this aspect further.
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CHAPTER I 
INTRODUCTION
Part II
1.2.1 CURRENT CONCEPTS OF INTERFERON
The discovery of interferon (IFN) by Isaacs
and Lindenman in 1957 was a direct consequence of 
preceding studies on interference of the infectious 
agent in the allantoic cavity of the chick embryo 
(Isaacs et al., 1957; reviewed by Henle et al., 1984).
The initial papers suggested that IFN may 
have been a single substance produced by all cells in 
response to all viruses (reviewed by Burke, 1985). 
However, it was shown that IFN made in calf kidney 
cells was inactive in chick cells and it was inferred 
that IFN was only active in the tissue in which it was 
formed, demonstrating species-specificity (Tyrrell, 
1959) .
It is now known that IFN is a family of
proteins and glycoproteins. They are divided into
three major classes, initially determined by the cell 
type in which they are predominantly produced: 
leucocyte for IFN-o( , fibroblast for IFN-^ and 
lymphocytes for IFN— (Zisman et al. , 1985) .
In 1983 a more rational nomenclature was 
introduced, since it was found that agents other than 
viruses could induce IFN. A distinction was therefore 
made between Type 1 (induced by viruses and double­
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stranded RNAs) and Type II (induced by mitogens)
(Burke, 1985). There are at least 20 types of IFN-cX.
2 subtypes of IFN - , and a single subtype of IFN-./1
(Knight , 1984) .
1.2.2 IN VITRO ASPECTS
IFN is well established as a natural 
consequence of viral infection, but the degree of IFN 
induction varies between agents. The basic 
requirements for induction is an effective interaction 
between the virus particle and the cell (Ho, 1984) . 
There are a number of factors which can affect the 
ability of viruses to induce IFN, such as metabolic 
effects of viruses on the cells, addition of hormones, 
carcinogens and ultra-violet light (Ho, 1966) .
Besides animal viruses, a large number of 
microbial agents, including viruses from fungi, 
bacteria and plants, and unicellular organisms can 
induce IFN (Ho, 1984).
Despite their wide variety, all IFN-inducing 
microorganisms appear to be cell associated parasites. 
It is possible that they have a common feature in their 
host cell relationship which is critical for IFN 
production (De Clercq et al., 1970).
Some gram-negative bacteria such as Brucella, 
Salmonella, Serratia, Bordetella, Francisella and 
Hemophilus and few gram-positive bacteria such as
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Listeria, Staphylococcus and Corynebacterium have been 
reported as IFN inducers (Ho, 1984).
1.2.3 In VIVO ASPECTS
Using biological and immunological assays it 
has been possible to determine the biological activity 
and potency of the particular IFN which is under 
investigation (Grossberg et al., 1984). The choice of 
a particular IFN assay depends on several factors such 
as the number of samples to be assayed, the range of 
levels of activity, the need for precision and 
sensitivity, rapidity, ease of performance, economy and 
each investigator must decide which type of assay best 
suits his own circumstances (McNeill, 1981) .
1.2.4 BIOLOGICAL ASSAYS
The biological assays are based on the 
ability of a preparation to inhibit the production of a 
virus or a viral product (Friedman et al., 1983).
Biological assays are laborious and less 
precise in comparison with most immunological assay 
procedures. They all depend on a biological property, 
the ability of IFN to inhibit the growth of viruses 
(Finter, 1973) . The characteristics of an assay 
method are therefore determined by the particular way 
it is used to measure virus growth. Different ways 
have been used in different IFN assays, and some of the 
resulting assays have proved to be much more 
satisfactory than others (Finter, 1973). In a typical
antiviral bioassay a series of dilutions of the IFN are 
made and each is added to one or more replicate tissue 
cultures of an appropriate cell (Finter, 1981). The 
cultures are incubated usually overnight and in those 
with a sufficient amount of IFN, an antiviral state 
develops in the cells (Finter, 1981). The cultures 
are then all challenged with a convenient virus e.g. 
Semiliki forest virus, Sindbis virus etc. After 
further incubation for an appropriate time, the extent 
of virus growth in each culture is determined in some 
way. The relation between the amount of virus growth 
and the amount of IFN is established graphically by 
calculation (Finter, 1981) .
In order to be able to carry out an IFN 
assay, it is essential to have some basic familiarity 
with tissue culture methods, sterile handling 
techniques, and the virus concerned. Moreover, from a 
sensitivity point of view, as well as convenience, 
continuous lines are preferred as the substrate for IFN 
assay (Finter, 1981). It is advisable to obtain fresh 
supplies of these cells at regular intervals of 2-3 
months in order to avoid inapparent contamination with 
mycoplasma or latent viruses which can alter assay 
results (Grossberg et al., 1984).
The viruses used for IFN assays should be 
laboratory adapted strains of relatively harmless 
agents (Finter, 1981). The quality of animal sera
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used in cultures and water employed in medium should be 
carefully controlled (Grossberg et al., 1984).
Clearly bioassays are extremely time consuming and 
technically demanding and suitable only for research 
1 a bora tor i e s .
The most popular assays for IFN are those 
which depend upon using a virus which causes extensive 
damage to the cultured cells so the potency of an IFN 
preparation is then determined by its ability to 
prevent virus infection (Grossberg et a 1 . , 1984).
The plaque-reduction method
The principle is that virus released from an 
infected cell in a monolayer is restricted to the 
vicinity of that cell because agar or some other 
viscous agent is included in the medium covering the 
cells. The released virus is able to infect 
neighbouring cells, so that clusters of virus-infected 
cells eventually surround each cell successfully 
infected by a virus particle in the inoculum. These 
clusters, which are termed plaques, can usually be 
counted with the naked eye, they are large enough but 
not so numerous that they fuse with one another, 
especially if the monolayers are stained with neutral 
red. Living cells take this up and are stained red, 
but cells killed as the result of virus growth lose 
their stain, and so the plaques are seen as pale areas 
on a red background (Finter, 1973).
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Established cell lines commonly used to assay 
human IFN by this method are human amnionic cells 
(WISH), human foreskin fibroblast. Rabbit kidney and 
mouse L929 cells are used for rabbit and mouse IFN, 
respectively (Langford et al. , 1981).
The most commonly used challenge virus for 
plaque reduction assays has been vesicular stomatitis 
virus (Langford et al., 1981; Grossberg et al., 
1984). Variations in IFN tit res with the plaque 
reduction assay is primarily dependent upon changes in 
sensitivity of the cells to IFN and virus.
To overcome some of the difficulties 
associated with doing plaque-reduction assays, 
microplaque-reduction assay for mouse and human IFN has 
been devised which gives titres comparable to those 
obtained with the usual plaque-reduction system 
(Grossberg et al., 1984) .
Virus-yield reduction assay
In yield reduction assays, virus growth is 
measured directly as infectious virus, haemagglutinin, 
haemadsorbing protein, viral enzyme (neuraminidase) or 
viral nucleic acid (Oie, 1977). These assays 
generally use high multiplicity of challenge to infect 
all the cells at the outset and determine the extent of 
inhibition of the viral parameter after a single cycle 
of viral growth (Grossberg et al., 1984).
51
Reduction of infectious virus yield
This assay consists of three sequential 
parts. The first one is to incubate IFN dilutions 
with sensitive cell cultures. After that the 
challenge of IFN-treated cells with a high multiplicity 
virus and finally measurement of the degree of 
inhibition of viral yield (Weigent et al . , 1981).
Routine assay of IFN by the yie1d-reduction 
method is not usually performed because At is expensive 
and slow and requires more time and effort than other 
IFN assays (Oie, 1977) . However, this assay is the 
method of choice when it is required to investigate the 
temporal changes in antiviral activity that occur 
within a cell following IFN treatment and the ultimate 
effect of these changes on the virus growth cycle 
(Weigent et al . , 1981).
The challenge virus most commonly used is 
Sindbis virus because it grows well in a variety of 
cell types used for IFN assays, it is very sensitive to 
IFN and forms plaques well m  primary chick embryo cell 
and baby hamster kidney cultures (Weigent et al.,
1981) .
The disadvantages of Sindbis virus in yield 
reduction assays is that virus infectivity decreases 
with storaget freezing and thawing. Therefore, virus 
samples should be assayed directly or stored at -70°C 
for a short period of time (Oie, 1977) .
52
Haemagglutinin (HA) yield reduction
The reduction in yield of influenza virus 
haemagglutinin from infected chicken embryo 
chorioallantoic membrane fragments was used by Isaacs 
and Lindenmann as the first method of measuring IFN 
antiviral activity (Jameson et al, 1981).
Many different types of IFN assay methods 
have been developed subsequently in an effort to 
improve sensitivity, precision, speed and convenience 
of measurements (Jameson et al., 1981). The typical 
assay consists of four steps: first preparation of
cell cultures, exposure of cells to IFN, infection of 
washed cell culture with virus and measurement of virus 
yield (Jameson et al., 1981) . Recently, an HA yield- 
reduction method using encephalomyocarditis virus has 
been applied to measurements of IFN in man, monkey, 
cow, pig, rabbit, cat, hamster, dog and mouse cells 
(Grossberg et al., 1984; Jameson et al., 1981). HA
yield-reduction assays are practical, sensitive, rapid, 
objective, reproducible and have been adapted to 
microtitre methods (Oie, 1977) .
Neuraminidase yield-reduction
The reduction in yield of influenza A virus 
neuraminidase is a sensitive and reproducible bioassay 
for various species of IFN (Grossberg et al., 1984).
A recombinant virus X7(Fl)(HON2) was the most 
IFN sensitive of 12 influenza viruses tested and also
produced higher yields of neuraminidase in most cell 
cultures than the other influenza viruses (Sedmak et 
al., 1981). This assay is based on the reduction of 
neuraminidase during a single cycle of influenza virus 
in chicken embryo cell cultures (Oie, 1977). This 
method is rapid, convenient, reproducible and is as 
sensitive as other methods (Oie, 1977) .
Inhibition of viral RNA synthesis
The assay of IFN by measuring its inhibitory 
effect on viral RNA synthesis was developed and found 
to be rapid, reproducible and highly sensitive (Giron, 
1981) .
The assay measures the incorporation of (3H) 
uridine into MM virus-infected cells in the presence of 
actinomycin D, which inhibits DNA-dependent RNA 
synthesis but allows picornavirus RNA synthesis to 
proceed (Grossberg et al., 1984).
Cytopathic effect (CPE) inhibition assay for interferon
These assays depend upon using a virus that 
causes extensive damage to the cultured cells. The 
potency of an IFN preparation is determined by its 
ability to prevent virus-induced CPE (Grossberg et al., 
1984).
Cell cultures are prepared and when 
monolayers have formed are treated with each of a 
series of IFN dilutions. After a suitable incubation 
period to permit establishment of the antiviral state,
the IFN is decanted and the cultures are exposed to an 
IFN-sensitive challenge virus and incubated for 24-48 
hours to permit development of extensive cytopathoiogy 
in unprotected cultures (Armstrong, 1981). The medium 
is then decanted, the cultures are fixed and stained 
with crystal violet and dried in air. Solvent is then 
added to each well to elute the dye, and the topical 
density of the eluent is measured to give a measure of 
the degree of cytopathology in cultures exposed to 
dilutions of IFN (Armstrong, 1981) .
For human IFN, various diploid human 
fibroblast may be used, including those of foreskin and 
embryonic skin/muscle origin and for human, rabbit and 
mouse IFN assay vesicular stomatitis virus is used as a 
challenge virus. The most important point in this 
type of assay is to choose a virus which causes a 
marked and characteristic CPE in the particular test 
cell (Finter, 1973). The assay is quite economical, 
entirely objective and quantitative.
Dye uptake method for assay interferon activity
The dye uptake method, a modification of the 
CPE inhibition assay, indirectly measures the extent of 
CPE damage to cells by the amount of vital dye, neutral 
red, taken up by cells. Cell taking up the dye can be 
microscopically enumerated, or cell-bound dye could be 
extracted and colorimetrical1y estimated (Oie, 1977).
In contrast to the CPE inhibition method, the 
dye uptake assay is objective in addition to being 
reproducible, sensitive and economical (Oie, 1977)
Cells commonly used are vervet monkey kidney line, V3, 
but Vero cells are also satisfactory and Semiliki 
Forest virus is used as a challenge (Johnston et al., 
1981).
1.2.5 IMMUNOASSAYS
In view of the lack of sensitivity of most 
biological assays to measure IFN below 10 IU/ml, 
immunoassays were recently introduced.
Radioimmunoassays by several different methods has been 
the most versatile and common method used.
Secher and Burke (1980) have produced a 
monoclonal antibody specific for human interferon alpha 
(HuIFN-o^. ) to Namalva IFN (NK2) and Secher has shown 
its usefulness for an immunoradiometric assay (IRMA) . 
The antibody was used to purify HuIFN-o^by immuno- 
adsorption chromatography and after labelling with 
■^2^I, immunoradiometric assay was developed (Secher,
1981).
This assay uses a crude sheep anti HuIFN-o( 
antibody of known potency bound to a solid phase 
(sepharose) to which an IFN preparation is added. The
amount of IFN bound to the solid phase could then be 
calculated from the amount of binding of radiolabelled 
monoclonal antibody (Grossberg et al., 1984).
IRMA offers considerable advantages over the 
conventional biological assays. Since the antibody- 
coated sepharose can be stored at 4°C, samples can be 
assayed at short notice and the results are obtained 
within 24 hours of beginning the assay (Secher, 1981). 
The assay is semi-automated and hundreds of samples can 
be assayed together at one time (Secher, 1981). This 
assay can measure concentrations of 50 IU/ml of IFN and 
it has a standard error of 10% for independent assays 
on the same sample (Grossberg et al., 1984).
A modification of this assay was performed by 
Walker and co-workers for the measurement of low 
concentrations of HuIFN-o( in serum. The sensitivity 
of the assay is 5 to 10 IU/ml and the coefficient of 
variation less than 10% (Walker et al., 1982).
Moreover, a rapid solid phase sandwich 
immunoassay for the detection and quantitative 
determination of HuIFN-o( was described. Two 
monoclonal antibodies were selected which recognize a 
different epitope of human leucocyte IFN and they bind 
to IFN simultaneously without mutual interference 
(Staehelin et al., 1981). One monoclonal antibody is
immobilized on a solid surface to which the IFN 
dilutions are added. The second one, labelled with 
125I or an enzyme, binds proportionately to the amount 
of IFN bound to the first antibody. After incubation
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and washing, IFN concentration is determined by 
measuring the amount of labelled antibody. This 
radioimmunoassay has already proven extremely useful 
for monitoring IFN during purification and the 
sensitivity approaches that of the CPE inhibition test 
(Staehelin et al., 1981).
The other type of radioimmunoassay reported 
for IFN is a competitive inhibition assay for HuIFN-<?C 
which use highly purified  ^2 5 I -1 abel 1 ed HuIFN- cK. , 
rabbit anti-HuIFN- (?(. IgG and protein A-containing as an 
IgG reagent (Daubas et al. , 1982) .
The sample to be assayed is incubated with 
purified rabbit anti-HuIFN- oi immunoglobulin and the 
highly purified hqifn-pC is added. The mixture
is incubated overnight after which Staphylococcus 
aureus containing protein A is added. The immune 
complexes bound to the ^aureus are washed, 
centrifuged; and the amount of label in the complex is 
determined (Grossberg et al., 1984). The lower
limit of sensitivity of this assay is 10 IU/ml. As 
the antibody is not monospecific for IFN, the 
specificity of the assay depends on the purity of the 
labelled IFN. The technique may offer a greater 
probability for recognizing more HuIFN- <X species than 
do assays using monoclonal antibody (Daubas et al . ,
1982).
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Mouse monoclonal antibody directed against 
HuIFN- o( was coupled to sepharose and used as an 
immunoadsorbent to purify HuIFN- o( . in addition, the 
IFN preparation was iodinated for'use as a probe in a 
radioimmunoassay for IFN- o{ (Meurs et al., 1982).
Another IRMA using a I labelled rat
monoclonal antibody (designated Yok 5/19) to leucocyte 
IFN- o( has been developed by Boots Celltech Diagnostics 
Limited. The assay has two site IFN capture, with a 
solid phase (sepharose) coupled to sheep anti-IFN.
The assay can detect as little as 0.5 IU/ml of IFN- 
in serum, this detection limit being the IFN- (A 
concentration that gives a radioactive signal at zero 
IFN- oL , and shows negligible cross-reactivity with 
HuIFN- jS ( < 0 . 015 %) and HuIFN- ^  (<0.005%). The intra­
assay co-efficient of variation was typically <10% over 
the range 3 . 55-7 . 30 IU/ml IFN-<?t during the first 8 
weeks of products shelf life (Abbott et al. , 1984) . A
radioimmunoassay has also been developed for HuIFN-^ .
This immunoassay consists of incubating 
HuIFN-y^ with rabbit anti-HuIFN-^ immunoglobulins 
immobilized on sepharose, and incubating the resulting 
solid phase IFN antibody complex with purified 
polyclonal 125 I-label1ed anti HuIFN ~ immunoglobulins. 
The amount of 125i labelled anti HuIFN-y^ bound to the 
complex was linearly proportional to the amount of 
antiviral activity present in the complex (Inoue et
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al., 1981). This assay can detect as little as 5 
IU/ml and the entire a s B a y  is completed in 5 hours 
(Grossberg et al., 1984).
At present monoclonal antibodies to HuIFN- ^  
suitable for immunoassays have not been developed.
Kelder and co-workers developed a technique 
for the detection and assay of HuIFN- ^  . The 
principle of the assay is identical to that described 
by Staehelin. Since a pair of monoclonal antibodies 
are used in this assay, only those IFN-J'1 molecules 
that are recognized by both monoclonal antibodies are 
detected. This radioimmunoassay could be used for 
monitoring IFN- ^  during purification or for 
surveillance of IFN- '(P levels in patients for 
pharmacokinetics studies (Kelder et al., 1986).
1.2.6 IN VIVO ASPECTS OF INTERFERON REPORTS DURING 
INFECTIOUS DISEASE
IFN has been presumed to play a major role in 
recovery from viral respiratory infection, especially 
in the primary infection with a specific respiratory 
virus. The peak of IFN responses occur early in the 
course of infection before detectable antibody and is 
probably responsible for the early reduction of the 
virus shedding (Moehring et al., 1971).
A study conducted in different sets of mice 
showed that in the primary infection with influenza 
aerosols, the peak levels of IFN in lungs lavages and
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the rapid production of antibodies in serum of mice 
were reached before detection of significant levels of 
neutralizing antibodies in serum and lung lavage 
(Iwasaki et al., 1977 ; Zee et al'. , 1979).
Higher IFN levels were found in sets of mice 
with higher mortality rate and it is apparent that the 
production of IFN is a direct consequence of virus 
replication in the lung tissues of infected animals 
(Zee et al., 1979).
High IFN titres were detected in the early 
stage of infection in calves after bovine RSV infection 
which dropped to undetectable amounts for at least one 
week and reappeared in low amounts and persisted for a 
number of weeks (El Azhary et al., 1981) .
Deficient production of IFN-<X has been 
described and has been associated with undue 
susceptibility to respiratory viruses (Isaacs et al . , 
1981) . The inability to produce IFN was found in 
children with prolonged or recurrent respiratory 
infections and in those treated with prednisone and it 
could explain the negative influence of cortico-steroid 
therapy on the course of acute viral infections 
(Vanecek et al., 1985).
Wheelock and Sibley in 1964 investigated IFN 
responses by bioassay in human serum during clinical 
viral infections (Wheelock et al., 1964). Later,
Matthews and Lawrence, measuring IFN levels in body
61
fluids as a rapid test, were able to demonstrate 
coincident production of IFN during acute viral 
infection (Matthews et al., 1979). Subsequently, in a 
series of serum studies, it was found that IFN 
determinations might be useful in establishing a viral 
aetiology (Parry et al., 1981; Levin et al., 1981; 
Flowers et al. , 1985) .
Significantly elevated IFN titres were found 
in sera and cerebrospinal fluids (CSF) of patients 
suspected of having viral infection, as compared to 
healthy controls. Moreover, these investigators 
suggest that detection of IFN in these fluids may be 
useful in suspected herpes encephalitis, where 
antiviral drugs should be administered as soon as 
possible (Negreanu et al. , 1983) .
Using a IRMA based on Yok 5/19 monoclonal it 
was possible to detect biological levels in vivo of 1.5 
to 100 IU/ml in CSF of patients with suspected 
meningitis (Ho-Yen et al., 1987). IFN- levels were 
found to be useful in distinguishing between bacterial 
and viral meningitis and were a better guide to viral 
meningitis than differential CSF cell count.
Local and systemic IFN production has been 
reported in children with a variety of acute viral 
respiratory infection (Ray et al., 1967; McIntosh et
al.# 1978) mainly in children infected with 
parainfluenza or influenza viruses, whereas only a few
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children with RSV infection had detectable IFN titres 
in their nasal secretions (Hall et al., 1978;
McIntosh, 1978) (Table 1).
As RSV is a member of the Paramyxovirus 
group, these observations are surprising since members 
of this group of viruses are normally very good 
inducers of IFN (Corbitt, 1971). The very low 
multiplicity obtainable in vivo, could explain the very 
low levels of IFN activity detected. These low levels 
may be inadequate to protect other cells in the 
respiratory tract from further RSV infections 
(Chonmaitree et al., 1981) .
However, appearance of IFN in nasal 
secretions in a limited number of RSV infected patients 
did not correlate with cessation of viral shedding 
(Hall et al., 1978) . Despite the evidence from other 
studies, it has been suggested that RSV is sensitive to 
the antiviral action of IFN (Corbitt, 1971; Gardner et 
al., 1970(a); Moehring et al., 1971).
The failure to detect IFN-^t in the majority 
of nasopharyngeal secretions (NPS) during RSV 
infection, may reflect the apparent natural lack of 
induction or a limitation of the method used. As 
biological methods lack sensitivity, a re-evaluation of 
IFN positivity of RSV in nasopharyngeal secretions 
(NPS) with more sensitive techniques may provide future 
useful information in the pathogenesis of RSV-
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bronchiolitis (Chonmaitree et al., 1981).
This study attempts to determine the 
usefulness of a sensitive solid-phase IRMA for IFN-«* 
in the context of an acute RSV infection to determine 
whether IFN positivity can be correlated with the 
severity of disease and provide a helpful indicator to 
physicians with respect to management or treatment of 
this disease during the course of the illness.
CHAPTER II
2.1 P ATIENTS, MATERIALS AND METHODS
2.1.1 Patients
The study group consisted of 208 children 
(128 males, 80 females) aged between 15 days to 6 years 
(mean: 8.8 months) admitted to the Royal Hospital for
Sick Children, Glasgow, between October 1985 to March 
1986 .
Details of the geographical location of 
residence of each patient were collected to follow the 
epidemiological and social impact of RSV on the 
paediatric population of Glasgow. However, of the 
total number of children only 193 came from the Glasgow 
area and the remainder from other parts of Scotland. 
Considering the five districts of the Greater Glasgow 
Health Board, the majority of cases were from Glasgow 
City (137) followed by Clydebank (25 cases), 
Strathkelvin (13 cases), Eastwood (11 cases) and 
Bearsden/Mi1ngavie (7 cases) .
Patients were not excluded for prior 
antibiotic treatment, or selected with regard to the 
number of symptomatic days prior to the admission. A 
full history and clinical examination was carried out 
in each case, and data recorded on a special form
Figure 1:
Plastic disposable collecting mucus trap with an attached 
feeding tube to obtain secretions
suitable for computer analysis (Appendix 1). This 
included admission history, diagnosis, classified into 
upper respiratory tract infection (URTI), pneumonia, 
bronchiolitis, chronic lung disease and other.
Bronchiolitis was considered in three major 
groups: mild, moderate and severe. Laboratory
findings of immunofluorescence technique, viral culture 
and IFN-c( levels were also included.
For this study special consideration was 
given to clinical parameters such as maximum 
respiratory rate, days of physiotherapy, time to 
establish normal respiratory rate etc, which might 
indicate the degree of respiratory impairment or 
constitutional upset.
2.1.2 Specimens
The study was approved by the Research and 
Ethics Committee of the Royal Hospital for Sick 
Children, Glasgow. Nasopharyngeal secretions were
collected on admission, or first day of symptoms if 
already admitted, and subsequently repeated on days 3,
5 and 7 when possible.
Plastic disposable collecting mucus traps 
with an attached feeding tube (5 fg) were used to 
obtain the secretions. The tube was passed into the 
posterior nasopharynx and suction at a vacuum pressure 
up to 25-50 mm of Hg was applied (Figure 1).
F i gur e_2_:
C h a r a c t e r i s t i c  R S V - s y n c y t i a l  for ma t io n .  M a g n i f i c a t i o n 100 .
If only the tube contained secretions it was 
cut from this trap and it was sent in a universal 
container to the laboratory. A portion of the 
secretions was cultured in bacteriological media and 
the remainder was transferred to virus transport medium 
(VTM) in a 1:10 dilution. After centrifugation of the 
specimen suspension (1500 x g for 15 minutes), the 
supernatant fluid was used for virus isolation and 
assay for IFN- o( . The cell pellet was examined by 
direct immunofluorescence using an RSV specific 
monoclonal antibody.
2.1.3 Viral isolation 
RSV isolation
Duplicate tubes of HEp-2 were inoculated with 
0.2 ml of specimen, incubated at 37°C and observed 
daily for characteristic RSV-syncytial formation 
(Figure 2). After seven days of incubation, one tube 
was kept for passage and the other tube was used for 
detection of RSV using immunofluorescence. The 
monolayer was removed with trypsin/versene and 
resuspended in 0.1 ml of phosphate-buffered saline 
(PBS).
A capillary tube was used to place two drops 
on multiwell test slide. These were allowed to air 
dry and then fixed in acetone for 10 minutes. This 
slide was examined by direct immunofluorescence (see 
Section 2.1.4).
Other respiratory viruses
Cell cultures of rhesus monkey kidney and 
MRC-5 (human embryonic lung) were inoculated with 0.2 
ml of the same specimen and were incubated at 37°C. 
Cultures were examined microscopically for typical CPE 
for 18 days before being discarded as negative. 
Adenoviruses were untyped but confirmed by electron 
microscopy examination of the tissue culture fluid.
2.1.4 RAPID DIAGNOSIS BY THE DIRECT IMMUNOFLUORESCENCE 
TECHNIQUE
RSV antigen was detected in exfoliated 
respiratory tract cells in cells from virus isolation 
tubes using a monoclonal antibody preparation "Imagen" 
commercially available (Boots Celltech Diagnostic 
Limited, Slough, U.K.) The Imagen reagent consists of 
a pool of purified murine monoclonal antibodies 
directed against the fusion and nucleoproteins of RSV; 
the antibodies are conjugated to fluorescein 
isothiocyanate and provided at a working dilution with 
Evans blue counterstain (Cheeseman et al, 1986). A
capillary tube was used to place two drops on a multiwell 
test slide. These were allowed to air dry and then 
fixed in acetone for 10 minutes. After acetone 
fixation, 20 /il of fluorescein isothiocyanate (FITC) 
conjugated monoclonal antibodies which bind 
specifically to RSV was put on the appropriate wells 
which were incubated in a humidified chamber at 37°C
P i g u r e _ 2 :
Rapid diagnosis of RSV by direct monoclonal antibody 
immunofluorescence technique showing granular cytoplasmic 
fluorescence. Magnification x 600.
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for 20 minutes. Slides were then washed once in PBS 
and distilled water for 5 minutes, allowed to dry and 
finally examined under a fluorescence microscope (Nikon 
Episcopic-Fluorescence attachment EP-D) at 
magnification of x 50 (oil). If RSV antigen was 
present, characteristic granular bright green contrast 
with the even red background staining (Figure 3) .
2.1.5 BACTERIOLOGICAL EXAMINATION OF NASOPHARYNGEAL 
SECRETIONS
Nasopharyngeal secretions underwent 
bacteriological examination using the following 
procedures. Each specimen was plated onto five 
culture media: one horse blood agar and one chocolate
agar were incubated in an atmosphere of 5-10% CO2 : one
horse blood agar was incubated anaerobically: A
MacConkey agar and a Sabouraud Dextrose agar were 
incubated aerobically. All plates were incubated 
overnight at 37°C. A single streak of StaphJL_aureus 
was incorporated on the aerobic horse blood agar plate 
perpendicular to the butt for the detection of 
satellitism as demonstrated by colonies of *£aemophilus 
i^ n f l_uenza e^
To aid presumptive diagnosis of group A 
Streptococci, a bacitracin (Oxoid Ltd, England) disc 
was placed onto the anaerobic horse blood agar plate. 
Beta-haemolytic Streptococci which failed to grow on 
MacConkey agar and which were inhibited by the
bacitracin in a zone at least 12 mm in diameter were 
considered to be Stregtococcu£_££0£enes.
Other beta-haemolytic streptococci were 
identified using the Streptococcal Grouping Kit (Oxoid 
Ltd, England) or, if this proved inconclusive, the API 
STREP (API Ltd, Basingstoke, England) identification 
kit .
An optochin (ethyl hydrocupreine 
hydrochloride) (Oxoid Ltd, England) disc was placed on 
the horse blood agar plate, incubated in CO2 for the 
presumptive identification of Streptococcus pneumoniae. 
Alpha-haemolytic colonies which showed a zone of 
inhibition around the disc at least 12 mm in diameter 
were identified as Streptococcus_pneumoniae. Isolates
of Streptococcus_pneumoniae were serotyped using 
agglutinating antisera (Inverclyde Biologicals).
Any organism showing satellitism around the 
Staph streak was stained by Gram's method. Gram- 
negative bacilli were speciated by determining their 
requirement for X and V factors.
Coliform bacteria were identified using the 
API 20E identification kit (API Ltd, Basingstoke, 
England).
Yeast isolates were identified by the germ- 
tube test. Germ tube negative isolates were sent to 
the Medical Mycology Unit at Anderson College, 
University of Glasgow for speciation.
Where necessary, antibiotic sensitivity tests 
were carried out using a disc diffusion technique.
2.1.6 Embryonated hen egg inoculations
Freshly fertilised eggs from a local farm 
were incubated for 9-11 days in a humidified incubator 
and turned regularly. Before inoculation, the eggs 
were checked for infertility by candling.
Embryonated hens' eggs were inoculated in 
triplicate with NPS by the amniotic route. Initially 
eggs were candled to mark the air space. Shells were 
then cut away above the air space and the 
chorioallantoic membrane was cleared with paraffin to 
mark the position of the embryo.
With a 1 ml syringe fitted with a 1.5 inch,
22 gauge needle, the inoculum was injected into the
amniotic cavity. The shell was sealed and the eggs
were incubated for three days at 33°C.
After this period, eggs were placed in a 4°C 
refrigerator overnight to prevent bleeding from ruptured 
vessels during harvesting. The shell membrane was 
removed aseptically and amniotic fluid was harvested 
using a tuberculin syringe and 23 gauge needle. 
Haemagglutination tests were performed using twofold 
dilutions in 0.05 ml volumes of PBS in a microtitre 
plate. Fowl red cell suspension at 0.5% was added to 
each test well including an erythrocyte control well
which contained 0.05 ml of PBS.
Erythrocytes in the test wells were mixed and 
plates were incubated at 4°C for one hour or until 
control cells have settled.
Plates were inspected and the 
haemagglutination titre was defined as the reciprocal 
of the highest dilution of each sample causing complete 
agglutination when mixed with an equal volume of 0.5% 
red blood cells.
Chicken red blood cells, but not guinea pig 
red blood cells will be agglutinated by influenza C 
virus. Influenza C and some newly harvested influenza 
A viruses may elute rapidly from the erythrocytes at 
ambient temperatures, so the settling of virus- 
erythrocytes was performed in the cold.
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CHAPTER III
3.1 INTERFERON ALPHA ASSAY PROCEDURE
IFN-ot levels were determined by an IRMA 
" Sucros ep-1 FN-<^ " commercially available from Boots 
Celltech Limited, Slough, U.K.) (Figure 4) . This assay 
has been used primarily to study IFN-<X levels in 
serum. In this study its use has been extended to 
determine levels in NPS.
Specimens were cleared as much as possible 
from cellular or other particulate material removed 
before analysis.
The test utilises an I labelled highly
specific monoclonal antibody (Yok 5/19) to leucocyte 
IFN- OL . There are two sites of IFN capture. Any 
IFN-<X present in the specimen is captured by 
radioactively labelled monoclonal antibody.
A second polyclonal linked to a high 
molecular weight particle is then added which binds 
labelled IFN-d  present. The solid phase (sepharose) 
polyclonal antibody sediments to the base of the test 
tube, carrying with it bound labelled IFN- (Figure 
5) .
The procedure was as follows: 200 u^l of the
specimen was added to each of 2 test tubes in a rack of 
20 tubes (Figure 6) . Immediately 50 /tl of

1st Incubation
IFN-oc
125l Monoclonal 
Antibody
►
MAb/IFN-oc Complex
2nd Incubation
Solid Phase 
Sheep
anti-IFN-oc
MAb/Antigen/ 
Antibody complex
Pignre_5:
Principle of the Sucrosep IFN-c/ IRMA.
F i g u r e _ 6 :
Addition of the specimen to the test tube
■ ■ ■ ■
F i g u r e _ 7 :
Addition of the radiolabelled monoclonal antibody to IFN-c<
F i^gure_8^:
Vortex-mixture of the specimen and the radiolabelled 
monoclonal antibody to IFN- c(
Figure_9
Addition of the polyclonal antibody to IFN-O^
F u  r e :
Repeated inversion of the capped bottle containing the 
polyclonal antibody IFN-o(
SUCRO AGITATOR
BOOTS-CELLTECH
DIAGNOSTICS
LIMITED
Fjigur e _1 1_:
Orbital shaker to keep the solid phase polyconal antibody 
in suspension while it reacted with IFN-£?( present
radiolabelled monoclonal antibody was then added and 
the tube contents vortex mixed for 60 seconds (Figure 7 
and 8) .
After an incubation period of 2 hours at room
temperature, 50 u^l of polyclonal antibody was added to
the mixture (Figure 9). The solid phase was mixed 
thoroughly by repeated inversion of the capped bottle 
immediately before and during pipetting (Figure 10) . 
Tubes were then placed on an orbital shaker for a 
further 2 hours in order to keep the solid-phase
polyconal antibody in suspension while it reacted with
IFN-c>( present (Figure 11) .
At the end of this period the test tubes were 
removed from the shaker and any empty tube spaces in 
the racks were filled with spare tubes before 
commencing the separation procedure. Labelled 
monoclonal antibody associated with IFN and solid phase 
was separated and washed by sucrosep non-centrifugation 
separation system (Wright et al., 1983).
To each tube was added 1 ml of pre-wash 
buffer to wash the wall of the test tube. The tubes 
were allowed to stand for five minutes. A sucropette
(Figure 12) was placed in each assay tube rack and 2 ml 
of sucrosep reagent was delivered to lower part of each 
tube (Figure 13). The dense sucrose solution 
displaces residual monoclonal antibody and the specimen 
to the upper part of the test tube. Carefully, the
sucropette was removed when the sucrose solution had 
been layered below the incubate and it was allowed to 
stand on the tissue pad in the inverted rack (Figure
14) .
The tubes were then left for 15 minutes to 
allow the solid phase polyclonal antibody to gravitate 
to the base of the tube, carrying with it any 
radiolabelled immune complex present.
The contents were aspirated leaving 
approximately 0.3 ml in the bottom of each tube (Figure
15) .
A second sucrose separation step was then 
carried out after which the tubes were sealed and their 
radioactivity counted in a gamma scintillation counter 
(Packard Auto-Gamma 5650, United Technologies, Packard) 
for a time sufficient to accumulate at least 50,000 
counts. A tube with 50 jil of the radio-labelled 
monoclonal was always added as part of the assay in 
order to determine the total number of counts.
A summary of the procedure is shown in Figure
12 516. Using a log/log plot ( I counts versus IFN- oL ) 
it was possible to interpolate the IFN- oC 
concentrations of the specimens using a standard curve 
(Figure 17) . It was performed with each new assay kit 
and in subsequent tests a control of 5 IU/ml was used. 
The assay standard is a human leucocyte IFN- oC 
preparation which has been calibrated against the MRC
F igur e_l 2_:
Sucropette used to deliver the separation solution
P igur e__l 3.:
Addition of the separation solution
risk of 
ionizing radiation
F i g u r e _1 :
Sucrose solution layering below the incubate
69/19 International Reference Preparation for human 
leucocyte IFN, obtained from the National Institute of 
Biological Standards and Control, London, U.K. The 
IFN- oi concentration range covered by the kit is 0-1000 
IU/ml.
A standard curve was prepared in VTM using 
recombinant IFN- ^  (Appendix 2) . Six points in 
duplicate ranging from 1 to 1024 IU/ml were used. A
1024 IU/ml stock was serially diluted to prepare the 
standard curve.
F i g u r e _1 5 '■
Aspiration procedure
INTERFERON ALPHA TEST
Addition of I125 labelled m o n o ­
clonal to IFN-o:
Incubate at room 
temperature for 
2 hours
Addition of solid phase 
with covalently coupled 
sheep anti-IFN
Vigorous agitation 
at room temperature 
for 2 hours
Addition of Pre-wash B u f f e r ®
Figure 16:
Sucrose Separation
Leave for five 
minutes un­
disturbed
(Gravity dependent)
Leave for fifteen 
minutes undisturbed
Aspirate supernant
Repeat steps 1 & 2
Count radioactivity of solid 
phase in gammacounter
Extrapolate test^count on standard 
curve for IF N - a  level
Summary of the IFN-c>( procedure
STANDARD CURVE FOR ALPHA-INTERFERON (DOUBLE LOG PLOT)
Counts
10,00 0 -
1,000
10 1j00025664 1001.00.1
IU/ml IFN -a
P i£ u re _ 1 7
CHAPTER IV
EXPERIMENTAL SECTION
4.1 PERFORMANCE PARAMETERS OF THE ALPHA INTERFERON 
IMMUNORADIOMETRIC ASSAY
Sucrosep IFN- oi IRMA has been developed by
Boots-Cel1tech Diagnostics for the measurement of human
IFN-o( in serum or tissue culture fluid. It is the 
first time that this test has been applied to measure 
IFN-oC in NPS from children with RSV infection and it 
was considered important to determine the assay 
performance when VTM was used as a diluent. This was 
based on the construction of a standard curve which was
employed to interpolate IFN- oi values. The
reproducibility of the test was performed by 
determining the percentage coefficient of variation 
when uninoculated fresh VTM were assayed the same day 
and sensitivity of the test by determining the minimum 
detection limit to consider a NPS positive for IFN-cX 
by this test. Specificity evaluations were performed 
by neutralisation-blocking experiments at various 
concentrations of recombinant and endogenous 
interferon.
4.1.1 Confidence limits and best-fitting line through 
a series of points
This experiment demonstrated the
TABLE 2
Statistical values for each point of ten standard curves 
performed monthly by Sucrosep alpha-interferon 
immunoradiometric assay
IU/ml Mean(cpm) S.D. S.E,
C.V,
(*)
0 101.8 32 10 31
1 132.6 32 10 24
4 243.4 52 16 21
16 642.0 174 55 27
64 2121.4 569 181 27
256 6783.1 1796 568.4 26
1024 12297.5 32 1004.0 26
cpm = counts per minute
S.D. = standard deviation
S.E. = standard error
C.V. = coefficient of variation
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reproducibility of the test when the mean values for 
each point of different standard curves performed 
during a period of ten months were plotted together. 
Method
The mean values for each point of different 
standard curves performed during a period of ten months 
were employed to calculate the best fit of the curve 
using a regression equation (Appendix 1).
Confidence limits (95%), standard deviation 
and standard error for each point were also calculated 
(Appendi x 1) .
Results
The best fit of a typical standard curve for 
the Sucrosep IFN- o( IRMA is shown in Figure 17.
Although the coefficient of variation is >10% they 
varied only from 21% to 31% and were very similar for 
each point (Table 2).
The variability was considered to be 
acceptable between intra-assay and inter-assay of these 
curves.
The 95% confidence limits are shown in Table 3.
4.1.2 A l p h a - i n t e r f e r o n  s p e c i f i c i t y  e v a l u a t i o n s  of 
known repetitive controls of virus transport medium 
with no alpha-interferon activity assayed the same day 
Method
200 ;il of VTM was added to each of 2 test 
tubes. The tubes were labelled from 1 to 20 and
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TABLE 4
Alpha-interferon specificity evaluations of known repetitive 
controls of virus transport medium with no alpha-interferon activity
assayed the same day
No. sample Counts per minute
1 91
2 105
3 88
4 77
5 108
6 104
7 88
8 87
9 102
10 98
11 93
12 86
13 94
14 86
15 86
16 88
17 H5
18 95
19 86
20 86
Mean: 93*15
S.D.: 9
C.V.: 9*6%
95% C.L.: 89*2-97*2
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samples were assayed for IFN-o^ as in Section 3.1.
The mean of the total number of counts, standard 
deviation and coefficient of variation were determined 
(Appendix 1).
Results
Table 4 shows the number of counts per minute 
of 20 determinations. The mean of total number of 
counts per minute was 93.2 with a standard deviation of 
9 and coefficient of variation of 9.6%. The 95% 
confidence limits were between 89.2-97.2 (Appendix 1). 
In a 2 year study a negative control sample did not 
exceed 102.2 counts per minute.
4.1.3 Minimum detection limit to consider a 
nasopharyngeal secretion positive by immunoradiometric 
assay
This experiment was carried out to evaluate 
the sensitivity of the test by determining the cut off 
level when it is applied to NPS.
M e t h o d
IFN- o(. positive NPS were prepared by a 1/10 
dilution of previously tested samples to give the 
following final concentrations: 0, 0.1, 0.2, 0.4, 0.6,
0.8, 1.0, 2.0, 4.0 IU/ml. 200 ^1 of these standard
controls was added to each of two tubes/standard and 
IFN- oi was assayed to prepare the endogenous IFN- c/ 
standard curve (Set 1). 400 ^1 of these same
standards was added to each of two additional
MINIMUM DETECTION LIMIT OF ENDOGENOUS
ALPHA-INTERFERON IN POSITIVE SPECIMENS
Counts
1,000-i
Standard curve
100- • Neutralised with 
sh eep  an ti I F N - *
10
0.2 0.4 0.6 0.8
lU/ml IF N -a
0.1
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tubes/standard. These tubes containing 400 ;ul were 
the samples for neutralization-blocking test (Set 2). 
Both sets of tubes were labelled with the different 
levels of IFN-o( .
100 jil of sheep anti IFN-c/ antibody (solid 
phase) was added to each one of the tubes with the 
specimens to be neutralized (Set 2). The samples were 
placed in a orbital shaker and incubated at room 
temperature for two hours. After this period, the 
samples were centrifuged and 200 ^1 of the supernatant 
was taken and assayed in duplicate for IFN-<?( activity 
following the procedure in Section 3.1.
Results
The results of IFN- detection in control 
and neutralized-blocked treated samples in a 
preselected range of NPS is shown in Figure 18. The 
limits of IFN-Ot sensitivity in NPS diluted in VTM, 
capable of being neutralized, is 0.2 IU/ml. After a 
1/10 dilution of a NPS, a minimum level of I FN- in 
the original sample must be 2 IU/ml by this test.
4.2 EXPERIMENTAL METHODS TO DEMONSTRATE THE PHYSICAL 
PROPERTIES OF ALPHA-INTERFERON
The use of monoclonal antibodies in 
immunoassays provide high sensitivity and specificity 
in detecting IFN in clinical specimens. It was 
considered important to evaluate some of the properties 
which characterized IFN-U  and to assess the ability of
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the Sucrosep IFN- oi IRMA in measuring differences 
during IFN inactivation.
Using recombinant IFN- U  and NPS from 
patients with proven RSV infections and prepared as 
described in Section 2.1.2, selected samples were used 
to evaluate some of the properties of endogenous IFN-cK''
i.e. heat and trypsin inactivation.
Methods and Results
4.2.1 HEAT INACTIVATION EXPERIMENT
The experiment attempts to determine whether 
exposure at 56°C of several standards of recombinant 
IFN-t^ and two different levels of IFN- in NPS will 
produce a change in activity when it is compared with a 
control curve.
Heat-inactivation curve of recombinant alpha interferon 
Method
IFN standards of 20, 100, 1000 IU/ml of
recombinant IFN-oi were prepared from the standard 
preparation of 1024 IU/ml. In order to prepare two 
sets of tubes in duplicate, 200 pi of each IFN standard 
(20, 100, 1000 IU/ml) was added to each of 4 test 
tubes. The tubes for inactivation were labelled with 
the different times to be tested (10, 20, 30, 40, 50,
60 minutes).
The rack of tubes was placed in a water bath
and the standards were heated to 56°C at the time
listed above. The IFN- ol assay was performed for the
control and heat treated standards using the same 
procedure as Section 3.1.
Results
The difference in international units per 
millilitre between the control and the heat treated 
recombinant IFN- o( of 20 IU/ml was calculated and 
plotted against time in minutes (Figure 19).
There was partial inactivation with a loss of 
15 IU/ml IFN- c/ (75% loss of IFN-cx' activity) at the 
end of the experimental time. Inactivation became 
evident after 20 minutes of treatment and continued to 
60 minutes when the test was terminated.
Heat-inactivation at the same temperature and 
using recombinant IFN-c/ of 100 IU/ml is shown in 
Figure 20. There was also partial inactivation with a 
loss of 50 IU/ml (50% loss of IFN- activity) after 60 
minutes treatment. Again an abrupt fall at 20 minutes 
of heat treatment was seen.
Heat-inactivation of a standard of 1000 IU/ml 
of recombinant IFN-o( versus time in minutes is shown 
in Figure 21. A signficant inactivation was seen 
after 20 minutes which continued throughout the period 
of heat treatment to 60 minutes. At 60 minutes, 44% 
of IFN-0^- activity remained (56% loss of IFN-o^ 
activity).
In these three experiments with recombinant 
I FN- 0^  partial inactivation of I FN- oL activity was seen
HEAT INACTIVATION CURVE AT 56°C USING A STANDARD
OF 20 IU/ml OF RECOMBINANT ALPHA-INTERFERON
Time (min)
4020 60
IU/ml
IQ-
15-
HEAT INACTIVATION CURVE AT 56°C USING A STANDARD
OF 100 IU/ml OF RECOMBINANT ALPHA-INTERFERON
Time (min)
10 50 603020 40
20-
lU/ml
30-
40-
Pi^£ure_2^£
HEAT INACTIVATION CURVE AT 56°C USING A STANDARD
OF 1000 IU/ml OF RECOMBINANT ALPHA-INTERFERON
Time (min)
6010 40 5020
100-
200-
lU/ml
300-
400-
500-
600 J
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by treatment with heat at 56°C for 60 minutes. A two 
stage inactivation was seen with a little loss of 
activity up to 20 minutes treatment (5-10% loss) 
followed by a steady loss of activity (50-75%) to 60 
minutes treatment when the experiments were terminated. 
This two stage inactivation appeared constant over the 
IFN- (^  concentration range of 20-1000 IU/ml (see Table 
5). The percentage of loss of IFN-c^ activity in the 
three periods were calculated as follows:
% loss of IFN-<y = _A_IU/ml 2^_0_m_i n] x_l 0 0
activity rIFN-o£ IU/ml
(0 - 2 0 )
% loss of I FN- (X = A IU/ml (40) - A IU/ml (21) x 100
activity rIFN-c/ IU/ml
(21-40)
% loss of IFN- <X = A IU/ml (60) - A IU/ml (41) x 100
activity rIFN- o( IU/ml
(41-60)
H e a t - i n a c t i v a t i o n  of t w o  d i f f e r e n t  l e y e l s  of a l p h a
i n t e r f e r o n  in n a s o p h a r y n g e a l  s e c r e t i o n s
Method
Two pools of NPS with levels of IFN at 52 and 
100 IU/ml were prepared. The I FN- ck assay was A.
performed to determine the exact value of the pool 
preparation. In order to prepare two sets of tubes,
200 ;ul of each pool (52 and 100 IU/ml) was added to
each of 4 test tubes.
HEAT INACTIVATION OF A POOL OF POSITIVE SPECIMENS
AT A CONCENTRATION OF 52 IU/ml 
Time (min)
6030 5010
10 -
20-
lU/ml
30-
40-
HEAT INACTIVATION OF A POOL OF POSITIVE SPECIMENS
AT A CONCENTRATION OF 100 IU/ml 
Time (min)
40 50 60
10-
20-
lU/ml
30-
40-
50
P igur e_2_3.
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The tubes for inactivation were labelled with 
the different temperatures to be tested (10, 20, 30,
40, 50, 60 minutes). The rack of tubes was placed in
a water bath and the samples were heated to 56°C at the
time listed above.
IFN-oi was assayed for the control and 
inactivated specimens using the same procedure as 
Section 3.1.
Results
The difference in IFN- C>( activity of a pool 
of positive NPS at a concentration of 52 IU/ml was 
tested during a period of sixty minutes at 56°C (Figure 
22) .
There was partial inactivation of IFN-i^C
activity with loss of 32 IU/ml (64% loss of IFN- c*!
activity) in the first period of 0-20 minutes and a 
further loss of 9 IU/ml (19% loss of IFN- oi activity) 
in the second period (20-60 minutes).
A pool of positive NPS at a concentration of 
100 IU/ml was also made and tested. The loss of IFN-oC 
activity in international units per millilitre during 
heat inactivation is shown in Figure 23. Similar to 
results obtained with the previous pool the fall in 
activity from 0-20 minutes was a loss of activity of 30 
IU/ml (30% loss of I F N - a c t i v i t y )  followed by a 
slower decrease in inactivation, i.e. a loss of 
14 IU/ml (14% loss of I F N - a c t i v i t y  between 20-60
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minutes of heat inactivation).
A two stage partial inactivation of IFN- 
activity was seen when endogenous IFN-c^ was heat 
treated. In the first period of 20 minutes a 30-64% 
loss of I F N - a c t i v i t y  was seen, followed by a further 
5-12% loss in the second period of 40 minutes.
Although, a two stage partial inactivation by heat 
treatment was seen for both recombinant and endogenous 
IFN, the rate of inactivation of endogenous IFN was 
higher in the first 20 minutes compared to recombinant 
IFN- oC (see Tables 5 and 6). Although inactivation of 
recombinant IFN-cX appeared to be resisted in the first 
20 minutes, a marked fall in IFN- activity in the
second 20 minute period i.e. between 20-40 minutes of
heat inactivation was seen (see Tables 5 and 6). The 
loss of activity in the three periods were calculated 
as follows:
% loss of IFN- = A  IU/ml (20) x  100
activity elFN-od IU/ml
(0- 20)
% loss of IFN- Oi = AlU/m! (40) - A  IU/ml (21) x  100
activity elFN- IU/ml
(21-40)
% loss of IFN- 0C = A IU/ml (60) - A IU/ml _(41)__x 100
activity elFN— IU/ml
(41-60)
TRYPSIN INACTIVATION CURVE USING THREE DIFFERENT
STANDARDS OF RECOMBINANT ALPHA-INTERFERON
^Recombinant IF N -a  
/  standard curve
100- Recombinant IFN -a  
treated with trypsin
1001.00.1
IU/ml IF N -a
Figure_£^t
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4.2.2 TRYPSIN INACTIVATION
The purpose of this experiment is to 
determine the effect of trypsin over the protein- 
content of IFN- o( present in NPS and recombinant I F N - ^  
standards compared to a control curve.
Trypsin inactivation curve of recombinant alpha
interferon
Method
IFN standards of 5, 10 and 100 IU/ml of
recombinant IFN- oI were prepared from a standard 
preparation of 1024 IU/ml. In order to prepare two 
sets of tubes, 200 jal of each standard (5, 10, 100
IU/ml) and 200 i^l of trypsin (see Appendix 2) was added 
to each of 2 test tubes/standard.
The rack of tubes was placed in a water bath 
for one hour at 37°C. After this period 100 ul of 
fetal calf serum was added in order to neutralize the 
trypsin. IFN- assay was performed using the same 
procedure as Section 3.1.
Results
Recombinant IFN-<X was found to be trypsin 
sensitive when the same standard curve without trypsin 
was employed. It was possible to inactivate 100% of 
the activity by trypsin in all the standards of 
recombinant IFN-(X (Figure 24).
Trypsin inactivation of three different levels of alpha
interferon in nasopharyngeal secretions
Method
Three pools of specimens with IFN- cA levels 
of 1.0, 1.5 and 7.5 IU/ml were prepared. The I F N - c ^
assay was performed (as Section 3.1) to determine the 
exact value of the pool preparation. In order to 
prepare two sets of tubes, 200 ^1 of each pool and 200 
i^l of trypsin were added to each of two test 
tubes/standard. The rack of tubes was placed in a 
water bath for one hour at 37°C. After this period 
100 p^l of fetal calf serum was added in order to 
neutralize the trypsin.
IFN-(X assay was performed using the same 
procedure as Section 3.1.
Results
Again, trypsin inactivation was obtained 
using endogenous IFN-o^ (Figure 25) .
It was possible to demonstrate inactivation 
of the endogenous IFN-oC activity in the three pools of 
specimen/standards.
As expected, for the properties of IFN- o£ » 
trypsin treatment completely inactivated both 
recombinant and endogenous IFN- o' as measured by this 
sensitive assay.
TRYPSIN INACTIVATION OF ALPHA-INTERFERON
ACTIVITY OF THREE POOLS OF POSITIVE SPECIMENS
Count
1,0001
Standard curve
Treated with trypsin
100-
7.5 100.1
Pigure_2_5
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4.3 EXPERIMENTAL METHODS TO DEMONSTRATE THE
SPECIFICITY OF ALPHA-INTERFERON
4.3.1 NEUTRALIZATION-BLOCKING EXPERIMENT
This experiment evaluates the specificity of 
the test when sheep anti IFN- o( is used to block any 
IFN- o( present in the standards and specimens. After 
a blocking step, samples were tested for any remaining 
IFN-pC activity.
Neutralization-blocking of recombinant alpha-interferon
activity
Method
IFN standards of 20, 100, 1000 IU/ml of
recombinant IFN were prepared from the standard 
preparation of 1024 IU/ml. 400 pi of each standard 
was added to each of 2 tubes/standard. These were the 
samples for neutralization-blocking experiments. Both 
sets of tubes were labelled with the different levels 
of IFN- cL ,
100 pi of sheep anti IFN- d  antibody (solid 
phase) was added to each one of the tubes with the 
specimens to be neutralized.
The samples were placed in an orbital shaker 
and incubated at room temperature for two hours.
After this period, the samples were 
centrifuged and 200 pi of the supernatant was taken and 
assayed in duplicate for IFN- oi. activity following the 
procedure in Section 3.1. At the same time IFN- O^was
NEUTRALISATION BLOCKING OF ALPHA-INTERFERON ACTIVITY OF THREE DIFFERENT
RECOMBINANT ALPHA-INTERFERON STANDARDS
Counts
10,000
Standard curve
1,000 -
Neutralised
100
10 1000100 
IU/ml IF N -a
201.0
F igure_2_6
assayed for the control samples.
The solid phase in this experiment was a 
sepharose bead system where sheep anti IFN- cL was 
covantly bound. It was possible t o ’capture IFN- o( 
onto the solid phase with incubation and remove it from 
the specimen by centrifugation. The supernatant could 
then be tested for residual unblocked I F N - .
Results
It was possible to neutralize -block 100% 
of the IFN- oi activity in the 20 and 100 IU/ml 
standards of recombinant IFN-c*; (Figure 26) , but 
residual IFN- <X activity (2.8 IU/ml (0.28%)) remained 
in the 1000 IU/ml control after blocking.
Neutralization of endogenous alpha-interferon activity 
(range 1-15 IU/ml) in nasopharyngeal secretions by 
sheep anti alpha-interferon 
Method
Five pools of RSV positive NPS with levels of 
IFN- o( at 1.0, 1.2, 4, 4.6, and 15 IU/ml were prepared
by appropriate dilution and repeat testing.
400 i^l of each pool was added to each of 2 
test tubes. 100 ;al of sheep anti IFN- oC antibody 
(solid phase) was added to each of the tubes to be 
neutralize-bioeked. The samples were placed in an 
orbital shaker and incubated at room temperature. The 
samples were centrifuged and 200 /il of each supernatant 
was taken and assayed for IFN-o< activity following the
NEUTRALISATION -  BLOCKING OF ENDOGENOUS ALPHA-INTERFERON
ACTIVITY (RANGE 1-15 IU/ml) IN NASOPHARYNGEAL SECRETIONS 
BY SHEEP ANTI ALPHA-INTERFERON
IU/ml
15-.
10 -
5 -
0
15
Specimen standard
Specimen neutralised 
with anti sheep IFN -a
4.6  4 .0  1.2 1.0
IU/ml IFN -a
procedure in Section 3.1. IFN- o( was assayed for the 
control samples.
Results
Neutralization-blocking of IFN- (X. activity of 
five pools of NPS specimens with levels of 1.0, 1.2, 4,
4.6 and 15 IU/ml is shown in Figure 27.
It was possible to neutralize -block 100% 
of the activity in three of the five pools of specimens 
(1.0, 1.2, and 4 IU/ml).
In the pool of specimens of 4.6 IU/ml and 15 
IU/ml the percentage of neutralization-blocking was 
93.5% and 93% of IFN- o/ activity respectively.
This experiment confirmed the specificity of 
the Sucrosep IFN- c{ IRMA by significantly reducing IFN- 
levels by treatment with anti-IFN- antibody.
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CHAPTER V
5.1 DISCUSSION OF THE EXPERIMENTAL SECTION
In a prospective evaluation of any new method 
to determine IFN-oC levels in a clinical study, it is 
important to determine the performance of the test in 
terms of sensitivity and specificity parameters with 
special reference to the clinical specimens to be 
examined. In previous studies specificity testing has 
taken account of the test's ability to demonstrate the 
properties of interferon in the clinical specimens.
In this study using 'Sucrosep IFN- o( IRMA' clinical 
specimens were subjected to heat stability and lability 
to trypsin for this purpose. Attempts were also made 
to determine pH lability but insufficient material was 
available for this study.
The reproducibility of the test was evaluated 
when the mean values for each point of different 
standard curves were plotted together (Figure 17) . A 
standard curve was used to interpolate IFN- oL values 
for unknown samples of NPS. The variability found 
between the standard curves of different kits of 
rss^snts were very similar for each point and varied 
from 21% to 31% (Table 2). This is a contrast to the
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biological assays wherein interassay coefficient of 
variations are often greater than 50% (Protzman et al . , 
1985) .
The interassay precision of the test was also 
evaluated when uninoculated fresh samples of VTM were 
assayed the same day giving a coefficient of variation 
of 9.6% (Table 4). This is in agreement with previous 
reports using the same assay. Ko-Yen et al . , 1987,
found that the coefficient of variation was <10% and 
Protzman et al., 1985, <6%.
The sensitivity of Sucrosep IFN-C^ IRMA for 
NPS was also evaluated and the test was able to detect 
as little as 0.2 IU/ml in a diluted clinical specimen 
(Figure 18).
Although the use of monoclonal antibodies in 
immunoassays provides high sensitivity and specificity 
in detecting IFN, it was considered important to assess 
the ability of the Sucrosep IFN-c/ IRMA to measure 
differences before and after IFN inactivation. In the 
present study, partial inactivation by treatment with 
heat at 56°C was found when either recombinant IFN-<?( 
or a pool of clinical specimens containing endogenous 
IFN- o/ were analysed. Inactivation became evident 
after 20 minutes of treatment and continued to 60 
minutes when the test was terminated. In the three 
experiments performed with standard preparations, a two 
stage inactivation was seen with little loss of
activity in the first 20 minute period of treatment (5- 
10% loss) followed by a steady loss of activity (50- 
75%) to 60 minutes treatment (Table 5). When the same 
experiment was applied to two different levels of IFN-ex^ 
in NPS, again a two stage of inactivation of endogenous 
IFN- oi was seen, but in this case the rate of 
inactivation of endogenous IFN- cK. was higher in the 
first 20 minutes and a slower rate between 20-60 
minutes treatment compared to the inactivation rate of 
recombinant IFN- ai (Tables 5 and 6).
It is likely that IFN present in NPS is a 
mixture of IFN- oC subtypes whereas the standard 
preparation is a recombinant monotypic IFN- o( . 
Differences in the subtype composition, chemical 
structure and buffering characteristics in suspending 
fluids may give rise to differences in the inactivation 
curves seen.
In order to confirm the protein 
characteristics of IFN- oi , standard preparations of 
recombinant IFN- 0( and clinical specimens containing 
endogenous IFN- OC were heated with trypsin for trypsin 
sensitivity. In these experiments, trypsin treatment 
completely inactivated both recombinant and endogenous 
IFN- oi (Figures 24 and 25). In similar experiments 
using biological assays McIntosh, 1978 found that 
trypsin treatment produced a 4-64 fold reduction in 
capacity of IFN in five secretions positive for
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influenza virus. Heating at 56°C for 30 minutes 
destroyed activity in only one secretion. On the 
other hand, Wheelock et al., 1964 found complete 
inactivation by trypsin treatment and partial 
inactivation by heating 9 sera samples at 56°C 
(McIntosh, 1978; Wheelock et al., 1964).
In this study neutralization-blocking 
experiments were performed in order to demonstrate the 
specificity of the Yok 5/19 monoclonal antibody in 
detecting IFN- oC . In both cases using standards and 
specimens, it was possible to neutralize almost all of 
the IFN- &(■ activity confirming excellent specificity in 
this test (Figures 26 and 27). Previous studies of 
IFN in NPS have used biological assays which are not 
always practical for routine application. Biological 
assays are labour intensive, slow and not many samples 
can be tested at once. Depending on the cell line and 
virus used in the assay, these assays detect total IFN
i.e. alpha plus beta plus gamma. Further tests are 
required to differentiate a particular IFN type 
(Protzman et al., 1985) . The radioimmunometric assay 
used for this study was rapid, reproducible, sensitive 
and specific to IFN- oi and the results were obtained 
within 24 hours. Prior to use of the * Sucrosep IFN- oi 
IRMA' to detect IFN- oL in clinical specimens, any 
particular matter present in the specimens such as 
mucus or debris was removed by centrifugation. Virus
100
transport medium was used as a diluent and in order to 
maintain reproducibility, a VTM blank control was used 
every time that the test was performed.
Samples were stored at -70°C after collection 
and when an appropriate number was accumulated the test 
was carried out. Repeated freezing and thawing of the 
specimens was also avoided by multiple aliquoting of 
homogenised samples. The stability of IFN varies 
considerably according to the type of IFN, the species 
of origin and the degree of purification, but IFN 
preparations can be stored for many months at -20°C or 
-70°C without loss of activity (McNeill, 1981).
The amount of NPS collected was usually very
small 0.1-0.5 ml and it was considered necessary to
dilute the NPS 1:10 in VTM prior to testing. This 
gave sufficient material for the other viral studies 
unde rtaken.
The assay kit employed in this study to
determine IFN-d in NPS contains radioactive material.
All the tests were carried out within a designated area
with monthly monitoring of the level of radioactivity
present on laboratory surfaces and equipment. A
record of the amount of radioactivity in microcuries
(uCi) was kept and sent to the regulatory authorities
12 5at the RHSC. One of the disadvantages of I is that 
it has half life of 59.6 days which gives a limitation
of time in which the test can be used.
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A number of features in the 1Sucrosep IFN-o{ 
IRMA' have been brought together to bring sensitivity 
and specificity with ease of handling. It is clearly 
advantageous to use a non-competitive monoclonal 
antibody together with a conventional hyperimmune 
antisera in a sandwich technique. In this way a 
monoclonal antibody can be selected for use as 
radiolabelled tracer (ensuring binding purity) allowing 
the hyperimmune sera with multiple epitopes attached to 
a solid phase to bring down the immune complexes formed 
with the monoclonal antibody (Hunter et al . , 1983) .
This solid phase separated easily and settled fairly 
quickly under unit gravity to allow its use in the 
sucrose solution. This gave the test both speed and 
efficiency (Wright et al., 1982).
It is clear from these studies that this 
assay is well devised and was reproducible, rapid, 
sensitive and specific in the quantitative and 
qualitative evaluation of IFN-<^ ( in clinical samples. 
The test was found to be highly satisfactory for use 
with NPS in this study.
CHAPTER VI
6.1. RESULTS OF THE CLINICAL ASPECTS
6.1.1. EPIDEMIOLOGY OF RESPIRATORY INFECTION IN 
GLASGOW
During October 1985 and March,1986, 208
children were admitted with suspected respiratory 
infection to the Royal Hospital for Sick Children 
(RHSC), Glasgow which is the main paediatric centre in 
Scotland. The number of respiratory admissions in 
children less than 15 years at the RHSC, Southern 
General (SGH) and Ruchill Hospitals from June 1985 to 
May 1986 is shown in Table 7. From the total number 
of respiratory admissions the RHSC admitted 1903 
children (79.5%). Paediatric departments at Ruchill 
and SG Hospitals have annual admissions for respiratory 
infections of 188 (7.8%) and 302 (12.6%) children
respectively.
When the same analysis was made for children 
less than four years for the same period of time, the 
RHSC during that year admitted 78.9% of respiratory 
infections compared to 9.4% at Ruchill and 11.7% at SGH 
(Table 8).
A comparison of total number of admissions 
and total number of children under study from October
COMPARISON OF TOTAL NUMBER OF ADMISSIONS FOR RESPIRATORY
INFECTIONS AND TOTAL NUMBER OF CHILDREN UNDER STUDY 
ROYAL HOSPITAL FOR SICK CHILDREN, GLASGOW, 1985-86
No. of 
children
300-i
200-
100-
Age <1
Age >1 and <4
Age >4  and <15
Total number of children 
under the study
*  Total/RSV + cases
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25/11
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TABLE 9
Total number and RSV positive cases in Glasgow area 
October 1985 to March 1986
Area No. children No. RSV (+)
G1 City Centre 1 1
G2 City Centre 1 0
G3 Yorkhill 4 2
G4 Townhead 1 1
G5 Gorbals 0 0
Gil Broomhill/
Partick
3 1
G12 Kelvindale/
Kelvinside
2 1
G13 Knightswood/
Jordanhill
5 4
G14 Yoker 6 4
G15 Drumchapel 16. 10
G20 Maryhill/
Ruchill
6 1
G21 Springburn/
Balornock/
Cowlairs
5
G22 High Possil 11 5
G23 Summerston 0 0
G31 Dennistoun/
Parkhead
6 4
G32 Carntyne/
Shettleston/
Carmyle/
Vernon/
Tollcross
6 1
G33 Garthamlock/
Robroyston/
Blackhill/
Riddrie/
Ruchazie
8 3
contd
G34
G40
G4l
G42
G43
G44
G45
G4l
G52
G53
G69
G71
G72
G73
TABLE 9 (contd)
Area No. children No. RSV
Garthamlock/ 5 • 3
Easterhouse
Bridgeton/ 3 1
Dalmarnock
Dumbreck/ 4 3
Pollokshields/
Shawlands
Toryglen 6 6
Pollokshaws/ 1 1
Newlands
Kings Park/ 1 1
Cathcart
Castlemilk 14 9
Shieldhall 5 . 3
Penilee/ 4 2
Cardonald/
Craigton/
Mosspark
Pollok/ 1 1
Nitshill/
Darnley
Baillieston/ 1 1
Chryston/
Gartcosh
Uddingston/ 0 0
Bothwell
Cambuslang/ 6 2
Blantyre
Rutherglen/ 4 1
Burnside
Total 137 73
107
TABLE 10
Percentage of households with two or more indicators of deprivation
LOCAL GOVERNMENT DISTRICTS
Glasgow City 28.8%
Clydebank 23.4%
Strathkelvin 12.5%
Eastwood 6.4%
Bearsden/Milngavie 5.8%
Scotland 19.6%
HEALTH BOARDS
GGHB 25.1%
Lanarkshire 20.6%
Argyll & Clyde 20.3%
Tayside 19.8%
Ayr and Arran 18.7%
Lothian 17.2%
Grampian 15-6%
Prom: Greater Glasgow Health Board (GGHB): 10 year report
1974-1983.
1985 to March 1986 is shown in figure 28. The 
majority of admissions (45%) were children under one 
year of age with the highest incidence of respiratory 
infections in November (30.7%) at the RHSC. From 
October 1985 to March 1986, 324 cases of bronchiolitis
were admitted to RHSC, and 95 of these (who were not 
excluded for prior antibiotic treatment or selected 
with regard to the number of symptomatic days prior to 
admission) were included in this study. It was 
therefore possible to study 29% of all cases of 
bronchiolitis at RHSC during the study period. These 
children were among the 208 with respiratory infection 
that constituted the study group.
6.1.2 GEOGRAPHICAL LOCATION
From the total number of children under study 
111 were found RSV positive, 5 adenovirus positive and 
1 influenza A virus positive. The majority of patients 
admitted to the study came from Inner Glasgow, 137, 
Clydebank, 25, Strathkelvin, 13, Eastwood, 11, and
Bearsden/Milngavie 7 cases.
The distribution of the total number and RSV 
positive cases in Glasgow is shown in Figure 29 and 30 
respectively. In Inner Glasgow 73 out of 137 children 
were RSV positive. Most positive cases were well 
spread out in the City but higher numbers were seen in 
G 1 5 - D r umchapel (10), G45-Castlemilk (9) G42-Toryglen 
(6) and G22-High Possil (5). Post codes and place
TOTAL NUMBER AND RSV POSITIVE CHILDREN IN INNER GLASGOW ADMITTED TO
THE ROYAL HOSPITAL FOR SICK CHILDREN, GLASGOW. 1985-1986
015
16/10
Total
Figure 29
G15 -  Drumchapel 
G22 -  High Possil 
G42 -  Toryglen 
G45 -  Castlemilk 
number/RSV +
TOTAL NUMBER AND RSV POSITIVE CHILDREN IN OUTER GLASGOW ADMITTED TO
THE ROYAL HOSPITAL FOR SICK CHILDREN, GLASGOW, 19 85 -198 6
25/14:
Inner Glasgow
Clydebank
Strathkelvin
Eastwood
Bearsden/M ilngavie
Total number/RSV +
109
TABLE 11
Indicators of deprivation in each individual household in the 
Greater Glasgow Health Board Area
1. Head of household seeking work, permanently sick or
disabled.
2. Occupancy: a measure of the rooms available in relation
to the population resident in a household, taking into 
account the marital status, age and sex of each member of 
the household.
3. Head of household in socio-economic group: personal
service, semi-skilled, skilled manual, agricultural.
4. Household with single parent family and dependent children.
5. Household with more than 3 dependent children.
6. Household contains only pensionable persons.
From: The Greater Glasgow Health Board: 10 year report,
1974-1983.
TABLE 12
Total number and RSV positive children with respiratory 
infection in the government districts and other places
1985-1986
Districts No. cases RSV (+)
 % %
Glasgow
Clydebank
Strathkelvin
Eastwood
Bearsden/Milngavie
Paisley, Lochwinnoch, 
Stewarton, Strathaven
Other parts of West of 
Scotland
137 (65.9) 73 (65.8)
25 (12.0) 14 (12.6)
13 (6.2) 8 (7.2)
11 (5-3) 6 (3.4)
7 (3.4) 3 (2.7)
5 (2.4) 4 (3.6)
10 (4.8) 3 (2.7)
Total 208 111
names are listed in Table 9. The proportion of 
households with two or more indicators of deprivation 
is shown in Table 10 taken from the Greater Glasgow 
Health Board (GGHB), 10 year report 1974-1983. It 
also shows that there is a higher proportion of 
multiply deprived households in the GGHB area than in 
any other Health Board in Scotland. There are 6 
indicators as is shown in Table 11. In this study RSV 
infection was much greater in infants from Inner 
Glasgow particularly Drumchapel, Castlemilk, Toryglen, 
High Possil (65.8%) and Clydebank (12.6%) which have 
households with 2 or more indicators of deprivation.
The reverse situation was found in 
Bearsden/Milngavie and Eastwood where the proportion of 
RSV infections was 2.7% and 5.4% respectively (Table 
12). Bearsden/Milngavie and Eastwood have a very 
small proportion of households with two or more 
indicators of deprivation (GGHB, 1983).
A summary of the proportion of RSV positive 
cases in the total number of children for each area is 
shown in Table 12.
There is a considerable variation in hospital 
admission rates for infants living in different parts 
of the GGHB. In the areas with high admission rates, 
morbidity may genuinely be higher with a greater 
incidence of infections and accidents than elsewhere. 
Alternatively children with a particular illness may be
TABLE 13
Age distribution of 202 children with respiratory infection due to
respiratory syncytial virus, Royal Hospital for Sick Children, Glasgow
1985-1986
Number of children 
Age (months) RSV (+)(*) RSV (—)(%)
<1 3 (2.7) -
1-2 27 (24.3) 17 (18.7)
3-4 31 (27.9) 15 (16.5)
5-6 20 (18.0) 13 (14.3)
7-8 10 (9.0) 11 (12.1)
9-10 4 (3.6) 7 (7-7)
11-12 8 (7.2) 4 (4.4)
13-14 - 3 (3.3)
15-16 - 3 (3.3)
17-18 1 (0.9) 2 (2.2)
19-20 1 (0.9) 1 (1.1)
21-22 1 (0.9) 1 (1.1)
23-24 3 (2.7) 2 (2.2)
25-26 - -
27-28 - 1 (1.1)
29-30 1 (0.9) -
30+ 1 (0.9) 11 (12.1)
Total 111 91
TABLE 14
Age distribution of 202 children with respiratory infection,
Royal Hospital for Sick Children, Glasgow,
1985-1986
Number of children 
Age (months) IFNc<( + )(Z) lFNo<(-)(*)
<1 2 (2.2) 1 (0.9)
1-2 25 (26.9) 20 (18.3)
3-4 17 (18.3) 29 (26.6)
5-6 18 (19.4) 15 (13.8)
7-8 8 (8.6) 13 (11.9)
9-10 8 (8.6) 3 (2.7)
11-12 6 (6.4) 6 (5.5)
13-14 1 (1.1) 2 (1.8)
15-16 3 (3.2) -
17-18 - 3 (2.7)
19-20 - 2 (1.8)
21-22 2 (2.2) -
23-24 1 (1.1) 4 (3.7)
25-26 - -
27-28 - -
29-30 - 1 (0.9)
30+ 2 (2.2) 10 (9.2)
Total 93 109
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more likely to be admitted to hospital if they are 
living in low income areas (GGHB, 1983).
6.1.3 AGE AND SEX
Table 13 shows the distribution of age in RSV 
positive and negative cases. A higher proportion of 
RSV positive cases was seen from 1 to 6 months of age 
and a sudden drop in the number of cases after 8 months 
was seen. In RSV negative cases the proportion of 
children from 1 to 8 months were quite similar and 
decreased steadily to 24 months with a second peak at 
30 months.
The age distribution of the total number of 
children which presented with a positive or negative 
IFN- oL response to infection is shown in Table 14. 
Alpha-interferon was present in a higher proportion of 
younger children (1-2 months) , compared to IFN- 
negative cases (3-4 months) and again gradually 
decreased with age.
The age distribution of RSV positive/IFN-c( 
positive-and RSV positive/IFN- ^  negative is shown in 
Figure 31. Three peaks of cases were identified in 
both groups: 1-4 months, 11-12 months and 23-24
months. Infants and children under one year of age 
comprise the major group of individuals with 
significant clinical illness consequent to RSV 
infection. In any year, a group of susceptible 
children are born subsequent to the previous RSV
TABLE 15
Sex distribution for age of 173 children with respiratory infection,
Royal Hospital for Sick Children, Glasgow
1985-1986
Age Male Female
X____________ %
<1 2 (1.8) 1 (1.6)
1-2 32 (28.8) 13 (21.0)
3-4 30 (27.0) 17 (27.4)
5-6 22 (19.8) 12 (19.3)
7-8 15 (13.5) 6 (9.7)
9-10 5 (4.5) 6 (9.7)
11-12 5 (4.5) 7 (11.3)
Total 111 62
116
TABLE 16
Sex distribution of 202 children with respiratory infection, 
Royal Hospital for Sick Children, Glasgow 
1985-1986
Male(jg) Female (%) Ratio
RSV (+) 72 (64.9) 39 (35.1) 1.8
RSV (-) 53 (58.2) 38 (41.7) 1.4
Total 125 (61.9) 77 (38.2) 1.3
TABLE 17
Sex distribution of 111 children with respiratory infection,
Royal Hospital for Sick Children, Glasgow
1985-1986
Male(JE) Female (%) Ratio
RSV (+) 40 (55.5) 25 (64.0) 1.6
IFN- c< ( + )
RSV ( + ) 32 (44.4) 14 (36.0) 2.3
I F N - (-)
Total 72 (64.8) 39 (35.1) 1.8
TABLE 18
Sex distribution of 91 children with respiratory infection,
Royal Hospital for Sick Children, Glasgow
1985-1986
Male(jt) Female (%) Ratio
RSV (-) 
IFN- o( ( + )
18 (32.0) 10 (28.6) 1.8
RSV (-) 
IFN- o( (-)
38 (67.9) 25 (71.4) 1.5
Total 56 (61.5) 35 (38.5) 1.6
119
epidemic. The children are likely to be the cases 
admitted 12 months or 24 months later during a 
subsequent RSV epidemic. A peak for IFN— positive 
cases was seen at 1-2 months of age compared to a peak 
at 3-4 months of age for IFN- negative cases.
Overall, the absence of IFN- 0^  during RSV infection was 
more likely in patients over 6 months of age. IFN- o( 
positivity in RSV positive cases was associated with a 
lower mean age (4.6 m) when compared to IFN-cxC negative 
cases (8.2 m), and this was statistically significant 
(p<0.05).
Analysis of sex distribution for age (Table 
15) showed that more boys were admitted between 1 and 2 
months than girls. The proportion in the other age
groups was similar up to 8 years. Sex distribution of
RSV positive and RSV negative cases is shown in Table 
16 and shows a male predominance in both RSV positive 
cases (1.8:1 M/F) and in RSV negative cases (1.4:1 
M/F). It would appear that whatever the infective 
cause boys are more likely to be admitted to hospital 
than girls. Sex distribution for RSV positive/IFN-oi 
positive and RSV positive/IFN- C?C negative cases is 
shown in Table 17. The M/F ratio for both groups is
still in favour of boys. Despite this M/F imbalance a
similar proportion of males and females produce or fail 
to produce IFN- oC in NPS during RSV infection.
However, from this data girls are more likely to be
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TABLE 19
Hospital stay duration of 202 children with respiratory 
infection, Royal Hospital for Sick Children, Glasgow
1985-1986
Number of children 
Hos/stay (days) RSV (+)(*) RSV (-)(*)
<5 28 (25.0) 40 (44.0)
5-8 50 (45.0) 18 (19.8)
9-12 15 (13.5) 15 (16.5)
13-16 9 (8.0) 6 (6.6)
17-20 5 (4.5) 2 (2.2)
21+ 4 (3.6) 10 (11.0)
Total 111 91
chi squared = 19.9 
p<0.05
12 1
IFN-^ positive during RSV infection. The sex 
distribution of RSV negative cases is demonstrated in 
Table 18 where the M/F ratio is still in favour of 
boys, but girls producing less IFN-c/ than boys in 
these cases.
6.1.4 RESPIRATORY SYNCYTIAL VIRUS AND HOSPITAL STAY
Hospital stay duration in RSV positive and 
negative cases is shown in Table 19. The majority of 
children RSV positive were discharged after 5 or 8 
days, whereas the majority of RSV negative patients 
were discharged in less than 5 days. The difference 
was statistically significant (p<0.05). The 
relationship between RSV positive cases and the 
presence or absence of IFN- o(. with respect to duration 
of hospital stay is shown in Figure 32.
The highest proportion of IFN-o<f negative 
cases were discharged at 3-4 days compared to 7-8 days 
for IFN-(X positive patients. After 9-10 days there 
was no difference in the discharge pattern of cases. 
IFN- c/. positivity in RSV positive cases was associated 
with a longer hospital stay (8.6 days) compared (7.4 
days) in IFN- oi. negative cases. However, there was no 
significant difference between these two groups when 
the Mann Whitney test was applied (Appendix 1).
6.1.5 ALPHA INTERFERON LEVELS
Mean levels and range of IFN-(X. positive NPS 
in 99 patients is shown in Table 20. Of the total
TABLE 20
Mean and range levels of alpha interferon by immunoradiometric 
assay in 208 children with viral respiratory infection, 
Royal Hospital for Sick Children, Glasgow 
1985-1986
Virus Mean Range
_____________ IU/ml IU/ml
RSV ( + ) 28.8 2-320
RSV (-) 37.3 2-120
Adeno 167.6 8-240
Influenza A 120.0 _
12 3
TABLE 21
A comparison of respiratory syncytial virus detection in tissue 
culture and monoclonal antibody techniques of 65 children with 
positive alpha interferon response, Royal Hospital for Sick Children, Glasgow
1985-1986
IFN- o< Tissue (?) mIFA (?)
IU/ml culture
2-20 9 (60.0) 43 (86.0)
>20 6 (40.0) 7 (14.0)
Total 15 50
12 4
number of patients (208) with suspected respiratory 
infection these 99 produced IFN- oC in NPS with a mean 
level of 28.8 IU/ml (2-320 IU/ml) for RSV positive and
37.3 (2-120 IU/ml) for RSV negative cases. The five
adenovirus positive cases had a mean level of IFN- c*d
167.6 (8-240 IU/ml) and one case with influenza A had a 
I F N - ^  level of 120 IU/ml. It is clear from 
other studies with other viruses that during RSV 
infection, IFN- ol is produced in relatively low amounts 
in NPS. The levels of IFN- ol for the RSV positive and 
RSV negative children is shown in Figure 33. It can 
be seen that RSV positivity was almost exclusively 
related to bronchiolitis whereas in RSV negative cases 
a broad spread among clinical cases was seen.
Interferon positivity was found in 65% of children with 
RSV bronchiolitis patients compared to only 31% in 
children with bronchiolitis due to other unidentified 
causes.
Of the 111 positive NPS positive for RSV, 89 
were detected by monoclonal immunofluorescence assay 
(mIFA) alone. The remainder (22) were positive by 
culture and by mIFA. No false negatives were found
while using this mIFA. IFN- oC levels in RSV positive
NPS identified by tissue culture and mIFA is shown in 
Table 21. It was observed that NPS RSV positive by 
mIFA were more likely to be in the low positive range 
of 2-20 IU/ml IFN-oC than culture positive samples (86%
ALPHA-INTERFERON LEVELS IN NASOPHARYNGEAL SECRETIONS OF FIVE GROUPS OF CHILDREN 
ROYAL HOSPITAL FOR SICK CHILDREN. GLASGOW. 1985-1986
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TABLE 22 
Analysis of the total samples and
23A
Sample analysis No.
Single samples 140
Two samples 35
Three samples 25
Pour samples 4
23B
RSV positivity No.
Samples 182
Cases H I
23C
IFN-q  ^>  2 IU/ml No.
Samples 142
Cases 93
Total samples 301
cases
(*)
(60.5)
(53.4)
(%)
(47.2)
(44.7)
Total cases 202
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compared to 60%).
Nasopharyngeal secretions found RSV positive 
by culture demonstrated higher levels of IFN- (>20 
IU/ml) than mIFA (40% compared to 14%). As a positive 
tissue culture result is more likely to accompany a 
specimen at higher virus titre, an extrapolation of 
this data may suggest that a higher virus titre is also 
associated with higher IFN- oi levels in NPS.
6.1.6 ANALYSIS OF SAMPLES AND CASES
The analysis of the total samples and cases 
is shown in Table 22. From the 202 children in the 
study 301 samples of nasopharyngeal secretions were 
obtained. The resulting combinations for IFN- ^  and 
RSV in specimens and for cases is shown in Table 23. 
When the proportion of RSV positive IFN-cKpositive 
specimens and cases is compared with the proportion for 
RSV negative IFN- (X~ positive specimens and cases; a 
ratio of RSV positive/RSV negative for IFN- expositive 
specimens/cases can be obtained. This ratio was 1.77 
for specimens and 1.90 for cases. For these ratios to 
remain similar, samples subsequent to the first sample 
analysed are likely to follow a similar result to that 
first obtained whether I FN- oC positive or IFN- 
negative. This would suggest that if IFN- iX levels 
are linked with viral replication that individuals IFN- 
negative at first sampling were in a final stage of
illness, while those IFN- positive were still in the
TABLE 24
Clinical presentation of 208 children with respiratory tract
infection, Royal Hospital for Sick Children, Glasgow
1985-1986
RSV ( + ) RSV (-) Adeno Plu A Total (56)
URTI 5 21 3 - 29 (14)
Bronchiolitis 66 29 - - 95 (46)
Pneumonia 37 13 1 - 51 (24.5)
Chronic lung disease 1 13 - 1 15 (7.2)
Other s 2 15 1 - 18 (8.6)
Total 111 91 5 1 208
chi squared = 54.5
PC0.0 5
URTI = Upper respiratory tract infection
RSV = Respiratory syncytial virus
Adeno = Adenovirus
Plu A = Influenza A
TABLE 25
Clinical presentation of 208 children with respiratory infection,
Royal Hospital for Sick Children, Glasgow, 1985-1986
Clinical
presentation IFN-^ ( + ) IFN- oC (-)
Total 99 {%) 109 (%)
Bronchiolitis -Cr 00 (48.5) 47 (43.1)
URTI 9 (9) 20 (18)
Pneumonia 34 (34.3) 17 (16)
Chronic lung 
disease 4 (4.0) 11 (10.1)
Others 4 (4.0) 14 (12.8)
chi squared = 18.23 
p<0.05
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TABLE 2 6
Clinical presentation of 202 children with respiratory 
infection, Royal Hospital for Sick Children, Glasgow
1985-1986
Clinical RSV positive RSV negative
presentation IFN-■«*( + )(*) IFN--<*(-)(*) IFN-•ca + )(*) IFN--c*(-)(*)
Total 65 (58.6) 46 (41.4) 28 (30.8) 63 (69.2)
Bronchiolitis 38 (58.5) 28 (60.9) 10 (35.7) 19 (30.2)
URTI 2 (3.1) 3 (6.5) 4 (14.3) 17 (27.0)
Pneumonia 25
L
f\
COm 12 (26.1) 8 (28.6) 5 (7.9)
Chronic lung 
disease
- 1 (2.2) 3 (10.7) 10 (15.9)
Others - 2 (4.3) 3 (10.7) 12 (19.0)
chi squared = 1.88
p >0.05 .
URTI = Upper respiratory tract infection
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acute viral stage. This hypothesis may explain the 
higher proportion of infants RSV positive IFN- oC 
negative discharged at 3-4 days compared to 7-8 days 
for I FN- po s i t i ve patients.
6.1.7 CLINICAL PARAMETERS
When clinical presentation of respiratory 
tract infection was analysed (Table 24), 95 children 
had bronchiolitis, 29 had URTI, pneumonia 51, chronic 
lung disease 15 and 18 had other symptoms such as 
diarrhoea, convulsions and congenital heart disease. 
Bronchiolitis was associated with the highest number of 
RSV positive cases and the difference between RSV 
positive and RSV negative cases was found to be 
significantly different (p<0.05). Table 25 presents 
data on the presence of IFN-o/ in the 208 children with 
respiratory infection. A statistical difference was 
found between IFN- oi positive and negative cases 
(p<0.05) with the IFN-C< positive cases predominantly 
related to pneumonia rather than URTI, bronchiolitis or 
chronic lung disease.
The relationship between RSV/IFN- o' 
positivity and negativity in relation to clinical 
presentation is shown in Table 26. When these two 
groups were compared in a chi squared test for clinical 
presentation no significant difference was found 
(p>0.05).
Although 25/37 cases of RSV pneumonia were
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TABLE 27
Maximum respiratory rate in 202 children with respiratory 
infection, Royal Hospital for Sick Children, Glasgow
1985-1986
Maximum respiratory IFN- (+) IFN- o( (-)
rate (min) % %
Total 96 106
<60 46 (47.9) 66 (62.3)
£60 50 (52.1) 40 (37.7)
chi squared = 4.20
p<0.05
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TABLE 28
A. Time to establish normal respiratory rate in 199 
children with respiratory infection, Royal Hospital
for Sick Children, Glasgow, 1985-1986
Time to establish IPN- <y(. ( + ) IFN-c^ (-)
normal respiratory
rate (days) (%) (%)
Total 93 106
0-3 63 (67.7) 77 (72.6)
4-7 30 (32.3) 29 (27.4)
chi squared 5*03 
p>0.05
B. Physiotherapy in 150 children with respiratory 
infection. Royal Hospital for Sick Children,
Glasgow, 1985-1986
Physiotherapy IPN- ( + ) IPN- c( (-)
(days) (%) (%)
Total 64 86
0-3 41 (64.0) 68 (79.0)
4-7 23 (36.0) 18 (21.0)
chi squared 4.33 
p>0.05
C. Length of tube feeding in 200 children with respiratory 
infection, Royal Hospital for Sick Children, Glasgow,
1985-1986
Length of tube IPN-oC ( + ) I P N - (-)
feeding (days) (%) (%)
Total 93 107
0-3 67 (72.0) 86 (80.4)
4-7 26 (2 8 .0 ) 21 (1 9 .6 )
chi squared 1.93 
p>0.05
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IFN-p£ positive in NPS, 8/12 RSV negative cases were 
similarly positive for IFN- oL . One of these 8 cases 
of IFN- oL positive/RSV negative pneumonia cases was 
identified as adenovirus positive (Table 24). For IFN- oC 
positive cases it would appear that other unidentified 
viral pathogens were responsible for these pneumonia 
cases.
Among the clinical parameters, maximum 
respiratory rate, time to establish normal respiratory 
rate, physiotherapy and length of tube feeding were 
evaluated statistically for an association with IFN- o/ 
regardless of aetiology. Maximum respiratory rate in 
children IFN- oC positive and negative is shown in Table 
27. A statistically significant value was achieved 
for this clinical parameter. Tables 28A, B and C, 
showed no significant difference between IFN- 
positive and IFN- od negative cases, although a trend 
for worse clinical outcome was seen for physiotherapy 
and length of tube feeding.
The same parameters were similarly evaluated 
in RSV positive and negative children and results are 
shown in Tables 29 and 30. Other parameters were 
analysed and are reported later in this section. A 
respiratory rate equal or greater than 60/min was found 
in 59 of 180 children (Table 29A). A higher 
percentage of children was found in the RSV positive 
group (56.7%) compared to the RSV negative group
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TABLE 29
A. Maximum respiratory rate in 180 children with
respiratory infection, Glasgow 
1985-1986
Maximum RSV (+) RSV (-)
respiratory
rate (min) (%) {%)
Total 104 76
<60 45 (43.3) 46 (60.5)
>60 59 (56.7) 30 (39.5)
chi squared = 18.16
1*0.05
B. Time to establish normal respiratory rate in
197 children with respiratory infection, 
Royal Hospital for Sick Children, Glasgow 
1985-1986
Time to establish RSV (+) RSV (-)
normal
respiratory rate
(days) {%) {%)
Total 109 88
0-3 68 (62.4) 70 (79.5)
4-7 41 (37.6) 18 (20.5)
chi squared =20.9 
p<0.05
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TABLE 30
A. Physiotherapy in 150 children with respiratory
infection, Royal Hospital for Sick Children, Glasgow 
1985-1986
Physiotherapy RSV ( + ) RSV (-)
(days) (%) (%)
Total 81 69
0-3 53 (65.4) 56 (81.1)
4-7 28 (34.6) 13 (18.8)
chi squared = 17.33
p<0.05
B. Length of tube feeding in 200 children with respiratory
infection, Royal Hospital for Sick Children, Glasgow 
1985-1986
Length of tube RSV (+) RSV (-)
feeding (days) (%) (j)
Total 111 89
0-3 81 (72.9) 72 (80.9)
4-7 30 (27.0) 17 (19.1)
chi squared =13.48 
p<0.05
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(39.5%) and this was statistically significant at 
p<0.05. Time to establish normal respiratory rate was 
analysed in 197 children (Table 29B). Children RSV 
positive (37.6%) took 4-7 days to establish normal 
respiratory rate compared to 20.5% RSV negative over 
the same period (p<0.05).
Days in which physiotherapy was administered 
was evaluated in 150 children (Table 30A) and 
physiotherapy was required for a longer period in RSV 
positive cases (34.6%) compared to RSV negative cases 
(18.8%) (p<0.05).
Length of tube feeding in 200 children is 
shown in Table 30B. Tube feeding was applied for a 
longer period in those children RSV positive (27%) 
compared to RSV negative (19%) (p<0.05).
A similar analysis using the same clinical 
parameters was made for RSV positive cases and IFN-oC 
status, i.e. IFN- c*. positive or negative. Results are 
shown in Tables 31 and 32. Maximum respiratory rate 
in 104 RSV positive children is shown in Table 31A. A
maximum respiratory rate greater or equal than 60 
breaths per minute was found in a higher proportion in 
RSV positive IFN- oL positive patients (61.9%) compared 
to IFN- oi negative patients (48.8%).
Time to establish normal respiratory rate was 
evaluated in 103 children (Table 31B). Children RSV 
positive IFN- oL positive (43%) took 4-7 days to
138
TABLE 31
A. Maximum respiratory rate in 104 children with respiratory
infection, Royal Hospital for Sick Children, Glasgow
1985-1986
Maximum RSV (+) RSV (+)
respiratory IFN-o< ( + ) IFN-o<(-)
rate (min) {%) (%)
Total 63 41
<60 24 (38.1) 21 (51.2)
^60 39 (61.9) 20 (48.8)
chi squared = 1.74 
p>0.05
B. Time to establish normal respiratory rate in 103 children
with respiratory infection, Royal Hospital for Sick Children,
Glasgow, 1985-1986
Time to establish RSV (+) RSV (+)
normal respiratory IFN-o((+) IFN-p((-)
rate (days) (%) (%)
Total 63 40
0-3 36 (57.0) 26 (65.0)
4-7 27 (43.0) 14 (35.0)
chi squared = 0.63
p>0 .05
C. Physiotherapy in 52 children with respiratory infection,
Royal Hospital for Sick Children, Glasgow 
1985-1986
Physiotherapy RSV (+) RSV (+)
(days) IFN-o(( + ) IFN-©((-)
(*) (*)
Total 31 21
0-3 11 (35.5) 13 (62.0)
4_7 20 (64.5) 8 (38.0)
chi squared = 3*52 
p».05
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TABLE 32
Length of tube feeding in 58 children with respiratory infection, 
Royal Hospital for Sick Children, Glasgow 
1985-1986
Length of tube RSV (+) RSV (+)
feeding (days) IPN«<( + ) IFNc<(-)
(%) (%)■
Total 35 (60.3) 23 (39.7)
0-3 13 (37.1) 15 (65.2)
4-7 22 (62.9) 8 (34.8)
chi squared = 4.38
p<0.05
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establish normal respiratory rate compared to RSV 
positive IFN- oC negative patients (35%). Fifty two 
children RSV positive IFN-cX positive (64.5%) required 
physiotherapy for a longer period (4-7 days) than 
children RSV positive IFN-c< negative (38%) (Table 
31C). Length of tube feeding in 58 children with 
respiratory infection is shown in Table 32. Tube 
feeding was applied for a longer period (4-7 days) to 
those children RSV positive IFN-expositive (62.9%) 
compared to RSV positive IFN-cX negative cases (34.8%) . 
There was a significant difference between both groups 
for tube feeding but a statistically significant value 
was not achieved (p>0.05) with other parameters when 
IFN-oC status was evaluated in RSV positive patients.
Although only one of the clinical parameters 
analysed was statistically significant for both RSV and 
IFN- ol , there is a strong tendency linking severity of 
the RSV infection with the presence of IFN-ol in NPS.
Other clinical parameters such as degree of 
bronchiolitis, maximum temperature, mechanical 
ventilation duration, maximum white cell count and 
lymphocytosis, intravenous fluids duration, maximum 
capillary C02 did now show any significant correlation 
with RSV positive/negative, IFN- oC positive/negative, 
RSV positive/IFN-expositive and RSV positive/IFN-oC 
negative status.
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TABLE 33
Viral and bacterial agents in 208 children with respiratory
infection, Royal Hospital for Sick Children, Glasgow, 1985-1986
Agents Bronchiolitis URTI Pneumonia Chronic Other
(*)
lung
(%) (*) diseased) {%)
RSV 38(40.0) 3(10.3) 21(41.2) 1(6.6) _
RSV + S.pneumoniae 11(11.5) 1(3.4) 5(9.8) - -
RSV + H.influenzae 11(11.5) - 6(11.7) - -
RSV + conforms 4(4.2) K3.4) 5(9.8) - 2(11.1)
RSV + other Strep 1(1.0) - - - -
NK 1(1.0) - - - -
Adeno - K3.4) - - 1(6.6)
Adeno + S.pneumoniae - K3.4) - - -
Adeno + H.influenzae - - 1(1.9) - -
Adeno + coliforms - 1(3.4) - - -
Adeno + other strep - - - - -
NK - - - - -
Influenza A - - - 1(6.6) -
S.pneumoniae 9(9.4) 5(17.2) 2(3.9) 3(20.0) 2(11.1)
H.influenzae 3(3.1) 5(17.2) 2(3.9) - 2(11.1)
Coliforms 2(2.1) - - 2(13.3) 1(6.6)
No organisms 15(15.7) 9(31.0) 9(17.6) 8(53.3) 10(66.6)
Other Strep - 1(3.4) - - -
NK - 1(3.4) - - -
Total 95(45.7) 29(13.9) 51(24.5) 15(7.2) 18(8.6)
NK = not known
6.1.8 MICROBIOLOGY
Viral and bacterial agents in the total 
number of children is shown in Table 33. RSV was 
found alone in 40.0% of bronchiolitis which constituted 
the largest group with a known aetiology. The second
group (41.2%) was RSV pneumonia where again RSV was
found alone.
During the study period, RSV infections were 
associated equally with ^pneumoniae (11.5%) and 
EjLillj!.i££E2££ (11.5%) of all cases of bronchiolitis.
RSV and coliforms and other Streptococcus were found in
a few cases, 4.2% and 1.0% respectively of
bronchiolitis.
£i.E£Pi.£££££££_EE££E£Iii££ and H^influenzae were 
identified in a similar proportion of RSV associated 
pneumonia cases i.e. 13.5% and 16.2% respectively, or 
9.8% and 11.7% of all cases of pneumonia.
S.pneumoniae was found alone in 9.4% of 
bronchiolitis cases while H^influenzae was found alone 
in only 3.1% of similar cases. In 15 cases of 
bronchiolitis (15.7%) no pathogens were identified.
H.influenzae and Streptococcus_pneumoniae were found in 
a similar proportion of URTI, pneumonia and other 
causes. Despite the fact, that adenovirus and 
influenza virus have been reported as causative agents 
of bronchiolitis, in the present study only 5 
adenovirus and 1 influenza A (untyped) were detected.
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Adenovirus isolates were confirmed by electron 
microscopy but no further experiments were performed to 
type these isolates.
Of the 5 adenoviruses, 3'were found in URTI 
cases. Influenza A virus was found in a case of 
chronic lung disease. Embryonated hen egg inoculation 
was performed in order to increase the isolation of 
influenza viruses in the population studied.
Despite considerable effort this procedure was 
unrewarding in this study. The only influenza A virus 
detected in this study, during a poor influenza season, 
was by the method of monoclonal immunofluorescence 
detection in NPS deposits.
Insufficient serum samples were received in the study 
to make an adequate analysis of results. The study has 
concentrated on the detection of virus by direct 
methods in NPS and by tissue culture techniques. In a 
paediatric population such as this study it is likely 
that these techniques are in themselves sufficient to 
provide the best diagnostic opportunity for acute 
respiratory infections.
CHAPTER VII
7.1 DISCUSSION OF THE CLINICAL ASPECTS 
AND CONCLUSION OF THE THESIS
The present results support RSV as an 
important cause of epidemic respiratory disease in 
Glasgow particularly in young children. The RHSC has 
the highest annual admissions in Glasgow for 
respiratory infections in children (79.5%) compared to 
other paediatric departments such as Ruchill (7.9%) and 
SGH (12.5%) Table 7).
In comparing the observations from the 
Greater Glasgow Health Board to this study, a good 
correlation between peaks of respiratory infection and 
RSV cases during the winter season was noted at this 
laboratory (Figure 28). During that period, 29% of 
all bronchiolitis cases from the total number of those 
admitted at the RHSC together with other respiratory 
infections were studied for RSV and IFN-(X. status.
Although no direct comparison of risk by 
socioeconomic class has been formulated, the majority 
of RSV infections were higher in infants from socially 
deprived areas of Glasgow: Drumchapel, Toryglen,
Castlemilk and High Possil (Figure 29). These areas 
have a higher proportion of low income families and
households with 2 or more indicators of deprivation 
(Table 10 and 11). The reverse situation was found in 
Bearsden/Mi1ngavie and Eastwood areas which showed the 
lowest numbers of admission rates for RSV infection.
In these latter areas the socioeconomic characteristics 
of the residents are better with 61% of the population 
belonging— to social classes I or II (GGHB, 1983).
In the socially deprived areas, a higher admission 
rate can be explained by the following reasons.
Firstly, the general practitioner or hospital doctor 
concerned may believe that hospital admission is more 
appropriate for children living in these areas. The 
home environment may not be conducive to rapid 
recovery; i.e. overcrowding, poor nutrition, smokey 
environment, dampness, poor parental understanding of 
problems and solutions. Secondly, it may be more 
usual for general practitioners in some areas to employ 
locums, some of whom may be unfamiliar with the 
practice and may therefore be more likely to seek 
hospital admission for the child. Thirdly, patients 
from certain areas may be more likely to present 
themselves directly to the hospital (GGHB, 1983).
Several host factors, including age, sex and 
the specific aetiology of acute respiratory infection 
may interact to determine the pathophysiological 
characteristics of a particular clinical illness. It 
has been reported that most infants hospitalized with
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RSV infection were less than six months of age 
(Glezen et al . , 1981) . The data presented here 
describes the influence of age, sex and aetiological 
agent on the occurrence of respiratory infection in 
these children. A higher proportion of RSV cases was 
found in children from one to six months of age whereas 
a higher proportion of RSV negative cases were from 
those six to eight months of age (Table 13).
The present study is one of the few that 
examines IFN-?4 responses during the course of 
naturally occurring human viral disease.
Interferon responses in children examined in 
this study were found in a similar proportion of 
bronchiolitis cases, but were more likely to be found 
in cases of pneumonia (p<0.05) and less likely during 
URTI (Table 25). The only clinical finding for which 
IFN-CX! itself appears to be statistically significant 
was maximum respiratory rate (Table 27). Trends were 
seen in IFN- (X positive cases for the remaining 
clinical parameters indicating 'worse clinical 
response' but these were not significant in statistical 
analysis (Tables 28A, B and C) .
IFN- 04 levels in NPS secretions were
determined in RSV positive and negative cases. IFN-c^C
positivity was found in a higher proportion of very
young children compared to IFN— OC negative cases (Table
14). These findings differ from the one described by
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McIntosh who did not find significant difference 
between children from 0-2 months and 6 and 8 months. 
Similarly, Hall et al., 1978, suggest that age alone 
did not appear to be a determining factor in the 
ability to produce IFN. The three peaks observed in 
both RSV positive IFN-t< positive and RSV positive IFN- ^ 
negative groups (1-4, 11-12 and 23-24 months) (Figure
31) indicates that in any year a group of susceptible 
children are born subsequent to the previous RSV 
epidemic. With the passing of each RSV epidemic, the 
susceptible pool decreases with fewer admissions as age 
increases. This signals an 'acquired immune state' to 
'clinical disease' or a removal of the anatomical or 
physiological factors that predispose younger infants 
to bronchiolitis.
A male predominance was found in this study 
(Table 15). Boys were admitted to hospital in higher 
numbers, whether RSV positive or negative (Table 16).
For respiratory disease, it would appear that whatever 
the infective cause boys are more likely to be admitted 
to hospital than girls. When sex distribution was 
analysed with regard to IFN-K , a similar proportion 
of males and females produce or fail to produce IFN- <X 
in NPS during RSV infection (Tables 17).
As girls are equally likely to become 
infected it is not clear why boys are seen to have a 
worse prognosis. This study has not highlighted any
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clues as this enigma.
Children RSV positive were hospitalized for a 
longer period than RSV negative cases and the 
difference between them was statistically significant 
(Table 19). Similarly, duration of hospital stay 
related to IFN- showed that RSV positive children 
stayed in hospital for a longer period compared with 
those IFN-<?(. negative. Although the differences were 
not significant, these results suggest that children 
who presented with IFN-c^ had more severe disease 
requiring hospitalization for a longer period than 
those IFN-o( negative cases (Figure 32) .
Analysis of general and paediatric hospital 
discharge records for children for 1981 shows that 
there is a very considerable variation in hospital 
admission rates within the Greater Glasgow Health Board 
Area. Children from areas of high admission rates 
i.e. Maryhi11/Ruchi11 area, tend to stay in hospital 
longer than children from low admission areas i.e. 
Eaglesham/Clarkston. The explanation proposed was 
that morbidity in children of areas of high admission 
rates was likely to be genuinely higher with a greater 
incidence of infections requiring hospital admission
(GGHB, 1983).
The d e v e l o p m e n t  and c h a r a c t e r i s t i c s  of IFN 
r e s p o n s e s  in R S V - b r o n c h i o l i t i s  has not r e c e i v e d  m u c h  
a t t e n t i o n  in the me d i c a l  l i t e r a t u r e .  RSV has
generally been considered to be a poor inducer of IFN 
during systemic or local infections in infants (Ray et 
al., 1967; Hall et al., 1978; McIntosh, 1978).
Hall et al., 1978 and McIntosh, 1978 observed 
that most children infected with parainfluenza or 
influenza viruses were able to produce IFN, whereas 
only a few children with RSV infection had detectable 
IFN titres in their nasal secretions. However,the 
present study using a sensitive immunoradiometric assay 
demonstrated IFN- oi in NPS of a relatively high 
percentage of children (38%) with RSV infection. In 
RSV positive b r o nchiolitic patients, IFN-c< was present 
in 65% compared to only 31% in bronchiolitic patients 
due to other causes (Figure 33).
Adenovirus infection in patients studied here 
was associated with IFN- pi mean level of 167.8 IU/ml.
Data from in vivo studies of RSV as an 
inducer of IFN production are limited and conflicting. 
Evidence indicates that IFN in the nasal secretions is 
an important factor to the course and recovery from 
viral respiratory diseases (Moehring et al . , 1971).
Infants hospitalized with bronchiolitis or pneumonia 
due to RSV developed low or undetectable levels of IFN 
in the nasal secretions (McIntosh, 1978). It has been 
postulated that the lack of detecting levels of IFN in 
the nasal washes of infants may contribute to the 
severity of the disease and to the abundant and
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prolonged shedding of RSV (Hall et al., 1978).
However, it has been suggested that the dilution of IFN 
by watery secretions could be so great as to render it 
undetectable even in a normal child (Reid, 1982). The 
application of the 'Sucrosep IFN- oL • test to NPS in 
this study enabled a comparison of four combinations 
for RSV and IFN status. As the ratios for (%) RSV 
positive/RSV negative cases for IFN- oi positive 
specimens and cases (1.77 and 1.90) and for IFN- 
negative and cases (0.64 and 0.60) were very close, it 
appears that when IFN- oL is induced during RSV 
infection, its presence is consistently associated with 
the persistence of the virus. Also, that IFN-oi is 
likely to be present at the first testing on admission 
in NPS of children who will produce IFN- oi in the 
course of RSV infection. Of the total population RSV 
positive, 58.6% was found to be IFN-c^ positive 
compared to 41.4% for IFN- oL negative cases. IFN- o( 
was associated with RSV bronchiolitis in 46% of cases 
compared to 29% of RSV negative cases (Table 24) . 
Interferon production is not an inevitable consequence 
of RSV infection, but when seen in a hospitalised case 
it is likely to persist while the case remains RSV 
positive. IFN-oiproduction during RSV infection in 
infants has been demonstrated by IRMA assay in this 
study in a significant proportion of bronchiolitis and 
pneumonia cases. The detection of IFN, contrary to
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other studies of similar cases appears to relate to the 
use of a sensitive and specific assay.
In this study a higher proportion of children 
RSV positive/IFN-o^ positive (61.9%) had a higher 
respiratory rate in contrast to RSV positive/IFN-&C 
negative cases (Table 31A). A rapid respiratory rate 
usually indicates a good compensation by the patient 
and in severe cases the respiratory rate may decrease 
(Wohl, 1981) . When the time in which normal 
respiratory rate was established, children RSV 
positive/IFN-oL negative responded quicker than RSV 
positive/IFN-cZ. positive cases (Table 31B) .
Physiotherapy was administered for a longer 
period in RSV positive/IFN-ai. positive children 
(Table 31C) and tube feeding was also required for 
longer in this IFN-C?^ positive, RSV positive group.
Despite the trends in various clinical 
parameters linking RSV disease severity with I FN- ex? 
positivity, the only clinical finding which was found 
to be statistically significant with the demonstration 
of circulating IFN-i?(was the duration of tube feeding 
(Table 32). This is a good indicator of disease 
severity since tube feeding is always required in 
severe cases of bronchiolitis.
This data l in k i n g  I F N - ( X p o s i t i v i t y  w i t h  m o r e  
s s r i o u s  d i s e a s e  c o n t r a d i c t s  ot h e r  p u b l i s h e d  data ci t e d  
ab ove . Altho ug h, it is l o gi c a l that IFN-cX
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production should be beneficial and therefore shorten 
the viral illness, it is also logical to assume that in 
serious disease with persistent viral replication IFN- c/ 
induction will continue until the virus is eliminated. 
The results in this study would support this latter 
argument. Persistent IFN-c><f detection in RSV 
infection could then be seen as an indicator of worse 
prognosis and an possible future indication for 
antiviral therapy.
As expected, the present results also showed 
that RSV positive patients were statistically 
different from those RSV negative patients in all the 
clinical parameters analysed. RSV positive children 
presented higher respiratory rates and a higher 
proportion of them failed to established normal 
respiratory rates before 4 or 7 days (Tables 29A and 
29B). Physiotherapy and length of tube feeding were 
applied for longer periods in those RSV positive 
patients (Table 30A and 30B).
The diagnosis of RSV in children has taken on 
an increasing importance as a result of the recognition 
of the frequency of infection in the paediatric 
population, and the possibility of treating severe 
infections with ribavirin and other antiviral drugs 
(Pothier et al . , 1985). The direct immunofluorescence 
technique has proved to be a very useful diagnostic 
test for rapid detection of RSV antigen in NPS. The
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significant advantage of immunofluorescence over 
i s o l a t i o n  is r el a t e d  to the speed of r e p o r t i n g  to the 
c l i n i c i a n  allowing the prevention of nosocomial 
infections. The other major requirement for 
successful identification by immunofluorescence is high 
quality and specific reagents (Treuhaft et al., 1985).
The commercially available direct 
immunofluorescence reagent (Imagen) has been shown to 
have similar sensitivity and specificity 
characteristics to the conventional indirect 
immunofluorescence for the detection of RSV in 
nasopharyngeal secretions (Cheeseman et al., 1985) .
In comparing the time taken to carry out the tests, the 
direct mIFA is shorter, requiring one incubation step 
of 20 minutes before examination, compared with 2 hours 
for the indirect method.
The diagnosis of RSV was demonstrated by the 
direct immunofluoresence technique when found culture 
negative, in 89 cases. The remaining 22 cases were 
positive by culture and by fluorescence (Table 21).
This reflected the high sensitivity of mIFA, compared 
to the Hep-2 cell culture system. It was observed 
that RSV positive NPS confirmed by fluorescence were 
more likely to be in the low positive IFN-o( range of 
2-20 IU/ml than culture positive samples which had a
h i g h e r  m e a n  IFN-o^ level.
Bed si d e i n o c u l a t i o n  of cell c u l t u r e  t u b e s
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with nasal washes has been reported to give excellent 
RSV recovery (Hall et al., 1975). Transport of the 
specimens at 4 C can also give the same results. In 
this medical centre, the specimens, as plain 
secretions, were sent without dilution in VTM and they 
arrived at the laboratory two or three hours after 
collection. This may have contributed to the low 
yield on culture.
In clinical situations NPS are usually 
obtained by a variety of personnel and transported by a
routine messenger to the laboratory. Once there,
additional delays may be encountered before inoculation
in cell cultures. Cell cultures supporting RSV
replication may themselves lose sensitivity with 
repeated passage and continual monitoring of this is 
required.
There are other factors in the recovery of 
RSV from clinical specimens by tissue culture which 
have to be considered. It has been observed that 
strains of RSV replicated optimally and produced 
cytopathology most rapidly when the Hep-2 cell 
monolayers were barely confluent at the time of 
inoculation (Treuhaft et al., 1985). Arens et al., 
1986 found that the use of combinations of cell culture 
were more efficient than any individual cell type for 
isolation of RSV (Arens et al., 1986). In the present
study, although specimens were inoculated in MRC-5 and
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monkey kidney in addition to Hep- 2 cells, an improved 
the rate of isolation was not seen.
This study confirms the epidemic behaviour of 
RSV in the community. One hundred and eleven cases of 
RSV were diagnosed with the identification of only 5 
cases of adenovirus and 1 case of influenza A. This 
study supports the view that RSV is the main 
aetiological agent for bronchiolitis, and does not 
require additional pathogens for disease to be severe.
To obtain a better isolation rate for 
influenza A, clinical specimens were inoculated into 
embryonated hen egg and tissue culture cells. 1985- 
1986 turned out to be a poor year for influenza 
isolates nationwide and this is reflected in this 
winter study. Influenza C virus is known, on the 
basis of serologic surveys, to be most prevalent among 
children. Attempts were made to isolate influenza C 
in the population studied without success. Influenza 
C is rarely associated with epidemics or outbreaks, and 
is rarely isolated: this is probably because the
majority of Influenza C virus infections cause mild 
illness resembling the common cold, and tissue cultures 
are poorly sensitive to this virus.
Serological diagnosis was not always possible 
to achieve because it was particularly difficult to 
obtain convalescent serum samples from children several 
weeks after their acute illness had ended.
The role of bacteria in bronchiolitis has 
been debated for many years and its significance has 
not- y©t been established. One of the difficulties in 
hospital based studies has been the administration of 
antibiotics to many affected children before admission 
to hospital, thereby minimizing the usefulness of 
results obtained from throat and nasal secretions as 
indices of bacterial infection (Simpson et al., 1978) .
££££P££££££H£_P£££E££i££ was the bacterium 
most frequently isolated (Table 33) but its 
significance as a pathogen has to be evaluated on the 
basis that many children are pharyngeal carriers of 
this organism.
In conclusion, the present study has 
demonstrated that circulating IFN-c<. could be detected 
in a considerable number of infants with RSV- 
bronchiolitis if a highly sensitive assay such as the 
IRMA used here. This test was performed on NPS 
obtained from infants with acute respiratory disease 
and was found to be rapid, reproducible and specific. 
The assay was capable of being perfomed within 6 hours 
of specimen receipt and could be batched for testing.
It could fit into diagnostic routines and provide 
information for both diagnosis in suspected virus 
disease and in management or as an indicator of the 
persistence of the virus and the effectiveness or 
otherwise of treatment regimes. The reproducibility of
the test was found to have a coefficient of variation 
of < 10% when tests were performed on the same day. 
Between assay precision was also acceptable, and 
provided the background for a routine test with minimal 
extra standardization.
The IFN-cXlRMA assay in this study was able 
to measure very low levels of IFN-o^(>0.2 l'U/ml) and 
was not affected by the proteinaceous nature of 
respiratory secretions.
The specificity of the test was further
proven by neutralisation-blocking assays which
confirmed the presence of IFN-o(in clinical specimens.
Clearly one of the disadvantages of this test is the
12 5use of a labile radioactive tracer I, reducing the 
shelf life of the reagents, requiring extra safety 
precautions and increasing the cost to potential users. 
However, the qualitative nature of radioimmunoassay 
gives precision to a method in which a cut-off of 
sensitivity can be measured allowing confidence at low 
levels of IFN detection. It is unlikely that the 
sensitivity of the system could be taken further 
without altering specificity and the value of measuring 
IFN-cX < 0.2 IU/ml is also questionable.
In this study sensitivity considerations were 
very important as previous work had suggested that IFN 
was ixregu1ar1y produced during RSV infection. The 
results of this study show that IFN-cxf induction during
RSV infection has been underestimated. However, the 
present study has confirmed predominantly low levels of 
IFN-cX produced in the course of this disease. This 
method would appear to be superior to previous 
biological methods used and has provided more 
information on the value of IFN measurements.
The IFN-cX. data is not conclusive, but this may have 
been improved if the clinical data was more critically 
kept in a prospective way compared, to the 
retrospective analysis that was made. Increased 
numbers in various clinical groups may have helped to 
achieve significance where trends were seen in multiple 
parameters.
This study does not give a clear indication 
where IFN fits into the pathogenesis of RSV infection 
and its associated bronchiolitis but has contributed to 
the knowledge of this infection and its significant 
impact on the infant below the age of one year. It is 
possible that IFN detection may have a place in the 
monitoring of a child's illness particularly if 
antiviral treatment is limited, by availability, cost, 
or toxicity, and when only selected patients can be 
treated.
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APPENDIX 1
1.1 Mean
The mean is a measure of location.
Sample mean = Sum_of_the_observations 
Number of observations 
The mean of the 20 determinations of uninoculated 
fresh VTM was 93.2
2.1 Standard deviation
The most useful way to assess variation or 
variability in replicate observation.
S = \Jl(x-x,)Z
n- i
x = mean
xl = each value
n " = number of determinations ,
The standard deviation of the 20 determinations of 
uninoculated fresh VTM was 9.
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1.3 Coefficient of variation
It is calculated to express the standard deviation 
as a percentage of the mean analysis.
CV = SD x 100 
x
CV = 9 x 100 = 9.6%
93 . 2
1.4 95% Confidence limits
The 95% confidence limits are lower and upper 
boundary values within which the mean has a high 
probability of being bracketed or enclosed.
95% CL = x+t (SEM)
x = mean
t = Student t-statistic and is found by
looking up the t-table
SEM = Standard error of the mean
SEM = s/ n
172
s « standard deviation
n * number of specimens
degrees of freedom = number of observation minus
1. So with n=20, there are 19 degrees of
freedom.
t (19) = 2.093
The confidence limits were calculated for each 
point of the standard curve and they are shown in 
Table 3.
1.5 Equation of the regression line 
Cubic fitted by least squares
The equation of the regression line was applied in 
order to determine the best fitting line of the 
standard curve through a series of points.
Equation y = log y x = log x
Z S
y = 4.79 +0.394x+ 0.118x -0.0112x 
x y Pred y
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0 . 1 101.8 104.4
1.0 132.6 120.3
4.0 243 . 4 252 .9
16 . 0 642 . 0 7T)1 . 1
64 . 0 2121.4 2142 . 4
256 . 0 6783 . 1 6034.6
1000 .0 12297.5 12970.2
The best fit of a typical standard curve is shown
in Figure 17.
1.6 Mann-Whitney U-test
It is a procedure for testing the null hypothesis
of equal population location parameters.
Test statistics:
1. The two samples are combined and rank all 
sample observations from smallest to largest.
2. Assign tied observations the mean of the rank 
positions they would have occupied had there 
been no ties.
3. Sum the rank of the observations from 
population 1. If the location parameter of 
population 1 is smaller than the location 
parameter of population 2, it is expected that 
the sum of the ranks for population 1 to be 
smaller than the sum of the ranks for
17^
population 2. Similarly, if the location 
parameter of population 1 is larger than the 
location parameter of population 2, it is 
expected the reverse to be true.
Depending on the null hypothesis, either a 
sufficiently small or a sufficiently large sum of 
ranks assigned to sample observations from 
population 1 causes us to reject the null 
hypothe s i s.
The test statistic is:
T = S- nl J.nl + 1)_
2
where S is the sum of the ranks assigned to the 
sample observations from population 1.
The null hypothesis is rejected if the computed T 
is less than the critical value of T using the 
table of quantiles of the Mann-Whitney test.
1.7 Thfe chi-squared distribution
The type of hypothesis tested in chi-squared 
distribution is that the two criteria of 
classification are independent. In order to test 
the null hypothesis it must be compared with the 
frequencies that were actually observed with the 
frequencies which should have been observed if the 
null hypothesis were true. The analysis involves
17 5
the use of 2 x 2 contingency table.
The level of probability regarded as significant 
wa s 0.05.
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INTERFERON STUDY
Hospital Number
Laboratory Number 12
Name
Ward
Sex 1. Male
2. Female
Date of Birth
Gestation
Birth weight (grms)
Age at time of 1st 
sample (completed months)
Date of admission
Date of discharge
Days of illness prior to 
hospitalization
Days of hospitalization 
Days of preceding antibiotic
Inpatient antibiotics
1. Yes
2. No
Diagnosis
1. Bronchiolitis
2. URTI
3. Pneumonia
4. Asthma
5. Cystic fibrosis
6. Bacterial meningitis
7. Aseptic meningitis
8. Bronchiolitis + URTI
9. Bronchiolitis + pneumonia
10. Bronchiolitis + congenital heart disease
11. Pneumonia + cystic fibrosis
12. Others
13
19
21
25
28
34
40
4 2 
45
47
48
50
177
Bronchiolitis
1. Mild
2. Moderate
3. Severe
Oxygen Therapy
1. Yes
2. No
Nasopharyngeal aspirate
1. Single
2. Two
3. Three
4. None
Serum
1. Single
2. Two
3. None
Urine
1. Single
2. Two
3. Three
4. None
CSF
1. Single
2. Two
3. None
Monoclonal fluorescence 
Antibody for RSV 
(Single specimen)
1. Respiratory Syncytial 
Virus positive
2. Respiratory Syncytial 
Virus negative
Monoclonal fluorescence 
Antibody for RSV 
(Multiple specimen)
1. RSV positive in the f irst
2. RSV positive in the first
3. RSV negative in the first
4. RSV negative in the first
5. RSV positive in the first
and 3rd
6. RSV positive in the first
7. RSV negative in the first
8. RSV negative in the first
9. RSV positive in the three
10. RSV negative in the three
]
]
□
57
NPA and negative in the 2nd 
and 2nd
NPA and positive in the 2nd 
and 2nd
NPA and negative in the 2nd
and 2nd and negative in the 3rd 
and positive in the 2nd and 3rd 
and 2nd and positive in the 3rd 
specimens 
specimens
59
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Monoclonal fluorescence 
Antibody for Flu A 
(Single specimen)
1. Flu A positive
2. Flu A negative 60
Viral culture 
1.
2 .
3.
4.
5.
6 .
7,
RSV 
Adeno 
Flu A 
Flu B
Enterovirus
Herpes
No virus isolated 61
Bacteriology
1. Streptococcus pneumoniae
2. Haemophilus influenzae
3. Coliforms
4. No organisms
Bacteriology (blood)
1. Streptococcus pneumoniae
2. Staphylococcus sp
3. Haemophilus influenzae
4. Coliforms
5. Neisseria meningitidis
6. No organisms
Interferon level 
(Single specimen)
1. Positive
2. Negative
Interferon level 
(Multiple specimen)
62
63
64
1. Positive in the first NPA and negative in the 2nd
2. Positive in the first and second
3. Negative in the f irst NPA and positive in the 2nd
4. Negative in the first and 2nd
5. Positive in the first and negative in the 2nd and 3rd
6. Positive in the first and 2nd and negative in the 3rd
7. Negative in the first and positive in the 2nd and 3rd
8. Negative in the first and 2nd and positive in the 3rd
9. Positive in the three specimens
10. Negative in the three specimens
I n t e r f e r o n  l e v e l  i n  t h e  f i r s t  
s a m p l e
I n t e r f e r o n  l e v e l  i n  t h e  s e c o n d  
s a m p l e
I n t e r f e r o n  l e v e l  i n  t h e  t h i r d  
s a m p l e
66
70
74
78
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Serum
Interferon level
Interferon level
Urine
Interferon level
Interferon level
Interferon level
CSF
Interferon level
Interferon level
first sample) 
second sample)
first sample) 
second sample) 
third sample)
first sample) 
second sample)
Serology by mIFA in the 1st serum 
(IgM)
1. RSV IgM positive
2. RSV IgM negative
3. Adeno IgM positive
4. Adeno IgM negative
5. CMV IgM positive
6. CMV IgM negative
7. Measles IgM positive
8. Measles IgM negative
9. Mumps IgM positive
10. Mumps IgM negative
11. Herpes IgM positive
12. Herpes IgM negative
Serology by mIFA in the first 
serum (IgG)
Respiratory syncytial virus 
Adenovirus
Cytomegalovirus
Measles
Mumps
Herpes
All measures on this page are coded as follows
1. <8 
2. 1:8
3. 1:32
4. _1:128
5. >1:256
82
86
90
94
98
102
106
108
109
110 
111 
112
113
114
180
Serology by mIFA in the 2nd serum 
(IgM)
1. RSV IgM positive
2. RSV IgM negative
3. Adeno IgM positive
4. Adeno IgM negative
5. CMV IgM positive
6. CMV IgM negative
7. Measles IgM positive
8. Measles IgM negative
9. Mumps IgM positive
10. Mumps IgM negative
11. Herpes IgM positive
12. Herpes IgM negative
Serology by mIFA in the 2nd serum 
(IgG)
Respiratory syncytial Virus
Adenovirus
CMV
Measles
Mumps
Herpes
All measures 
1. <8 
2. 1:8
3. 1:32
4. _1:128
5. >1:256
Complement fixation (1st serum) 
Influenza A
Influenza 
Adenovirus Group 
Mycoplasma pneumoniae 
Psittacosis-LGV 
Q-fever
Respiratory syncytial virus 
Parainfluenza 1 (Sendai) 
Herpes
Cytomegalovirus 
Varicella-zoster 
Mumps S 
Mumps V 
Measles
Leptospirae (gp-specific)
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136 
137
181
Complement fixation (2nd serum) 
Influenza A
Influenza B 
Adenovirus Group 
Mycoplasma pneumoniae 
Psittacosis-LGV 
Q-fever
Respiratory syncytial virus 
Parainfluenza 1 (Sendai) 
Herpes
Cytomegalovirus 
Varicella-zoster 
Mumps S 
Mumps V 
Measles
Leptospirae (gp-specific)
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
All
1. <8 
2. 1:8
3. 1:16
4. 1:32
5. 1:64
6. 1:128
7. 1:256
8. 1:512
9. 1:1024
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Highest oxygen given
Time in (days)
Maximum Resp Rate (1 minute)
Time to establish normal resp 
rate (days)
Maximum temperature
Days of Physiotherapy (days)
Length of tube feeding (days)
Mechanical Ventilation 
Duration (days)
Maximum white cell count (x )
Maximum capillary CO^ (rnm Hg) 
Social class (1,2,3,4,5)
Intravenous fluids duration (days)
Lymphocytos is
1. Yes
2. No
155
158
160
162
165
167
170
173
176
178
179 
181
182
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APPENDIX 2
2.1 Preparation of rhesus kidney cells
A. Remove the supernatant medium from flasks of 75 
cm2 with confluent monolayers of cells.
B. Wash the monolayer with 5 ml of phosphate buffered 
saline (PBS) Dulbecco's with phenol red, Ca and Mg 
free to reduce the number of these ions present. 
Remove it after 5 minutes.
C. Add 0.5 ml of a mixture trypsin/versene and 
incubate at 37°C for 5 minutes or until the cells 
can be seen dissociated.
D. Mix cells in 60 ml of medium 199 with Hanks' 
salts, with 0.35 g/1 NaC03, with glutamine and 
seed plastic culture tubes with 1 ml each.
E. Incubate at 37°C until used for viral isolation.
2.2 Preparation of MRC-5 and HEp-2 cells
A. Remove the supernatant medium from flasks of 75 
cm2 with confluent monolayers of cells.
B. Wash the monolayer with 5 ml of phosphate buffered
saline (PBS) Dulbecco's with phenol red, Ca and Mg
free. Remove it after 5 minutes.
C. Add 0.5 ml of a mixture trypsin/versene and
incubate at 37°C for 5 minutes or until the cells 
can be dissociated.
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D. Mix cells in 30 ml of minimum essential medium
(MEM) (Eagle) with Hanks' salts without L-
Glutamine and seed plastic culture tubes with 1 ml 
each .
E. Incubate at 37°C until used for viral isolation.
2.3 Tissue culture growth media
2.3.1 Minimum essential medium (MEM)
MEM (Eagle) with Hanks' salts 
without L-glutamine 
Fetal calf serum
(Mycoplasma and virus screened)
Penicillin/Streptomycin 
(5.000 units/ml)
Glutamine (200 mM/ml)
Sodium bicarbonate (4.4%)
Mix the above materials
8 7 ml
1 ml
1 ml 
1 ml 
1 ml
2.3.2 Medium 199
Medium 199 with Hanks' salts with 0.35 gm/1 
NaHCO3 with L-glutamine 
Fetal calf serum
(Mycoplasma and virus screened)
Penicillin/Streptomycin 
Glutamine (200 mM/ml)
Sodium bicarbonate (4.4%)
Mix the above materials
87 ml
10 ml
1 ml
1 ml 
1 ml
185
2.4 Tissue culture maintenance medium
2.4.1 Minimum essential medium (MEM)
MEM (Eagle) with Hanks' salts and without 87 ml
L-glutamine
Fetal calf serum 2 ml
(Mycoplasma and virus screened)
Penicillin/Streptomycin 1 ml
(5.000 units/ml)
Glutamine (200 mM/ml) 1 ml
Sodium bicarbonate (4.4%) 1 ml
Mix the above materials
2.4.2 Medium 199
Medium 199 with Hanks' 87 ml
with 0.35 g/1 NaHC03
Fetal calf serum 2 ml
(Mycoplasma and virus screened)
Penicillin/Streptomycin 1 ml
(5.000 units/ml)
Glutamine (200 mM/ml) 1 ml
Sodium bicarbonate (4.4%) 1 ml
Mix the above materials
2.5 Trypsin-EDTA solution
Contains 0.5 g Trypsin (1:250) and 0.2 g EDTA/1 of 
Modified Puck’s Saline A. This reagent is supplied 
ready for use.
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2.6 Direct fluorescent monoclonal antibody test for 
RSV "Imagen" Boots Celltech Diagnostics Limited
Anti-RSV mouse monoclonal FITC conjugate.
One bottle containing 1.25 ml of Imagen RS virus 
reagent. This reagent is supplied ready for use and 
should be stored at 2 - 8 ° C in the dark and left at room 
temperature for 5 minutes before use.
2.7 Sucrosep IFN- &(. IRMA (Boots Celltech Diagnostic 
Limited
Standard preparations
A. Reconstitute the freeze-dried IFN- <X standard of 
1024 IU/ml using 3.0 ml of virus transport medium 
as a diluent.
B. Mix the bottle by gentle inversion and allow it to 
stand for approximately 15 minutes at room 
temperature.
C. Prepare a series of standards as follows:
IFN-t*. Take volume VTM(ul) (IU/ml)
1024 stock 0 1024
1024 200 600 256
1024 100 1500 64
64 200 600 16
64 100 150 0 4
4 200 600 1
0 1000 0
IB 7
12 5
2.8 I Monoclonal antibody to IFN- pi (YOK 5/19)
This reagent is supplied ready for use.
2.9 Solid phase polyclonal antibody to I F N - ^
This reagent is supplied ready for use.
2.10 Concentrated pre-wash buffer
A. Make up the contents of the bottle labelled as 
pre-wash buffer to 300 ml with distilled water.
B. The final solution may be stored in a closed
container at 2-4°C and is stable for one month.
2.11 Sucrosep separation reagent
A. Make up the contents of the bottle labelled as 
sucrosep reagent to 600 ml with distilled water.
B. The final solution, colour coded light blue, may 
be stored in a closed container at 2-4°C and is 
stable for one month.
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APPENDIX 3
3.1 Commercial sources of the reagents
3.1.1 Cells (HEp-2, MRC-5, rhesus monkey kidney)
Flow Laboratories Ltd
Rockingham Road 
Uxbridge
Middlesex UB8 2 UE
Tel: 0895 384512/2
Telex: 922083 Answerback FLOWWD
3.1.2 Medium 199, MEM, fetal calf serum,
peni ci11 in/s treptomycin, glutamine, 
trypsin/versene, PBS, virus transport medium, 
Columbia agar (Oxoid) with horse blood, 
Columbia agar with horse blood, horse 
chocolate, Sabouraud Dextrose agar
Gibco Ltd 
Trident House 
P.O. Box 3 5 
Renfrew Road 
Paisley 
Renfrewshire 
Scotland PA3 4EF 
Tel: 041-889 6100
Telex 777968/777029
18 9
3.1.3 Sodium bicarbonate 
Wellcome Diagnostics 
Temple Hill
Dart f ord 
England DAI 5AH 
Tel: Dartford (0322) 77711
Telegrams: Wellco Dartford
Telex: Wellco G 896113
3.1.4 Plastic tissue culture tubes 
Labco Ltd
Marlow
England
3.1.5 Capillary tubes 
Chance Propper Ltd 
Smethwick
War1ey 
England
3.1.6 Bacitracin disks, Optochin disks 
Oxoid Ltd,
England.
3.1.7 FITC monoclonal antibody for RS virus
Imagen reagent, Sucrosep IFN- Oi IRMA 
Boots Celltech Diagnostics Ltd 
Slough
190
3.1.8
3.1.9
Berkshire, England.
Tel: (0753) 821221
International: +44 75 3 821 221
Telex: 847805
Mucus traps
Mucus Extractor
Feltham,
Middlesex, England.
Api Strep for bacteria identification 
Api Ltd 
Ba singstoke 
England.
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